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Metabolic Heterogeneity in Molecular Subsets of Diffuse Large B-cell Lymphoma 
ABSTRACT 
Cells adapt their metabolism to satisfy changing bioenergetic and biosynthetic needs. 
Investigation  of  metabolic  reprogramming  in  cancer  has  provided  insight  into  the  metabolic 
control of proliferation and survival. While the predominant focus of this field has been aerobic 
glycolysis (the Warburg effect), increasing evidence points to a complex landscape of tumor 
metabolic  circuitries  beyond  aerobic  glycolysis,  including  varied  degrees  of  mitochondrial 
contribution to tumor metabolism.   
To investigate alternative metabolic programs compatible with tumor growth, we turned 
to Diffuse Large B-cell Lymphoma (DLBCL), a highly heterogeneous disease encompassing 
discrete clusters or subtypes defined by tumor-intrinsic genetic distinctions. In one classification 
scheme, a B-cell receptor (BCR)/proliferation cluster identified BCR-dependent DLBCLs with 
elevated  expression  of  BCR  signaling  components.  A  second  subset,  OxPhos-DLBCL, 
displayed  increased  expression  of  mitochondrial  oxidative  phosphorylation  genes,  and  was 
insensitive to BCR inhibition. However, the functional attributes of OxPhos-DLBCLs and the 
nature of their BCR-independent survival were unknown. 
Upon  integrative  analyses  of  DLBCL  subtypes,  we  uncovered  quantitative  proteome- 
and  metabolome-level  signatures  associated  with  differences  in  nutrient  and  energy 
metabolism.  Specifically,  BCR-DLBCLs  have  greater  glycolytic  flux  typical  of  the  Warburg 
phenotype.  Unlike  BCR-DLBCLs,  OxPhos-DLBCLs  channel  the  majority  of  glucose-derived 
pyruvate  into  mitochondria,  display  elevated  mitochondrial  electron  transport  chain  (ETC) 
activity,  ATP  production,  and  fatty  acid  oxidation  (FAO).  Importantly,  these  metabolic 
distinctions  are  associated  with  subtype-selective  survival  mechanisms.  Moreover,  acute 
inhibition  of  BCR  signaling  in  BCR-DLBCLs  increased  their  FAO  capacity,  thus  revealing  a 
reciprocal relationship between BCR and FAO.  Dissertation Advisor: Dr. Nika Danial    Illana Allake Stanley 
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Further dissection of mitochondrial function in OxPhos-DLBCLs indicates that increased 
mitochondrial  metabolism  is  integrated  with  at  least  two  homeostatic  mechanisms  that  help 
maintain ETC activity and FAO capacity. In particular, OxPhos-DLBCLs harbor robust protein-
level enrichment of mitochondrial translation factors required for the synthesis of mitochondrial-
DNA-encoded ETC subunits. Inhibition of the mitochondrial translation pathway is selectively 
toxic to OxPhos-DLBCLs. A second mitochondrial homeostatic pathway, mitochondrial network 
dynamics,  also  proved  relevant  to  OxPhos-DLBCLs.  Compared  to  BCR-DLBCLs,  OxPhos-
DLBCLs display a fragmented mitochondrial network that supports their FAO capacity. Overall, 
these  findings  demonstrate  previously  unappreciated  metabolic  heterogeneity  in  molecular 
subsets of DLBCL and uncover BCR-independent survival mechanisms linked to mitochondrial 
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Carbon substrate metabolism in the programming of cell fate and function 
Different cell states have distinct anabolic and catabolic needs that can be fulfilled by 
processing specific carbon substrates such as glucose, fatty acids, amino acids, and ketone 
bodies. The cell’s choice of carbon substrates not only fuels biosynthetic pathways, but also 
enables  programmatic  adaptations  to  stress  conditions  that  go  beyond  compensating  for 
changes in nutrient availability. Recent advances in metabolomics and metabolic flux analysis 
combined with high throughput interrogation of the genome and proteome have provided some 
insights into molecular determinants of fuel choice and its contribution to cell fate and function in 
both  normal  and  disease  states.  In  particular,  the  cell’s  choice  of  carbon  substrates  can 
influence transitions between quiescence and proliferation, modulate cellular differentiation and 
lineage specification, produce resistance or sensitivity to oxidative stress, facilitate DNA and 
tissue  repair,  and  allow  adaptation  to  nutrient  changes  [1-3].  Furthermore,  metabolism  of 
particular  carbon  substrates  can  influence  cell  identity  and  behavior  through  programmatic 
alterations in gene expression and epigenetic modifications, at least in part, by affecting the 
activity of chromatin modifying enzymes [4]. Understanding how cells choose to preferentially 
utilize a particular carbon substrate and defining its specific metabolic outputs can provide a 
molecular  handle  on  metabolic  control  of  cellular  proliferation,  differentiation  and  survival  in 
normal physiology and under pathologic conditions.  
The following sections highlight the contributions of substrate metabolism to biosynthetic 
and bioenergetic needs of cell growth. Within this context, the emphasis is placed on metabolic 
pathways in charge of generation and utilization of precursors central to anabolic reactions and 
the contribution of mitochondria to both anabolic and bioenergetic requirements of cell growth. 
In  aggregate,  these  considerations  are  meant  to  showcase  the  breadth  and  diversity  of 
metabolic solutions to the specific demands of cellular proliferation and survival, particularly as it 
relates to cancer.  
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Meeting the biosynthetic requirements of proliferation: The role of aerobic glycolysis 
The  specific  needs  of  the  proliferative  state  for  lipids,  amino  acids,  reducing 
equivalents, and nucleotides necessitate reprogramming of carbon substrate utilization and 
production  of  metabolic  precursors  for  biosynthetic  reactions  [2].  Moreover,  given  the 
requirement for reducing potential in order to generate biomass, the metabolic program in the 
proliferative  state  includes  increased  NADPH  production  [2].  Aerobic  glycolysis  or  the 
Warburg  effect,  which  refers  to  increased  glycolytic  conversion  of  glucose  to  lactate  over 
mitochondrial  glucose  oxidation  even  in  the  presence  of  sufficient  oxygen,  was  originally 
recognized  as  a  chief  metabolic  alteration  in  cancer  cells,  and  recently  appreciated  as  a 
metabolic feature of proliferating cells in general [2, 5, 6]. It is increasingly recognized that the 
predominant contribution of aerobic glycolysis to proliferation is the provision of biosynthetic 
intermediates for new biomass rather than energy production [7]. For example, increased flux 
through the pentose phosphate pathway (PPP), a biosynthetic branch point of glycolysis at 
glucose-6-phosphate (Figure 1.1), contributes to NADPH synthesis, and thereby supports fatty 
acid and cholesterol synthesis as well as anti-oxidant mechanisms. The PPP also generates 
precursors for nucleotide biosynthesis (ribose-5-phosphate) [2] (Figures 1.1 and 1.2). Another 
glycolytic  intermediate,  3-phosphoglycerate  (3PG),  can  contribute  to  de  novo  serine 
biosynthesis  via  phosphoglycerate  dehydrogenase  (PHGDH)  [8,  9]  (Figures  1.1  and  1.2). 
Serine can in turn influence purine biosynthesis by generating glycine and one-carbon donors 
such as N
10-formyl-THF (Figure 1.2). The availability of glycolytically-derived metabolites for 
the  biosynthetic  reactions  described  above  is  dependent  on  glycolytic  flux  as  well  as  the 
regulated  entry  of  glucose-derived  pyruvate  into  the  mitochondrial  tricarboxylic  acid  (TCA) 
cycle. Several metabolic control points allow proliferating cells to enrich for upstream glycolytic 
intermediates  at  the  expense  of  pyruvate  utilization  by  mitochondria.  The  conversion  of 
phosphoenolpyruvate (PEP) to pyruvate by pyruvate kinase (PK), the final step of glycolysis, 






Figure  1.1.  Schematic  of  select  pathways  in  charge  of  glucose  and  glutamine 
metabolism, as well as metabolic outputs of citrate that relate to biosynthesis and 
antioxidant capacity  
Glucose-derived metabolites can be used to generate pyruvate or to supply precursors for 
the pentose phosphate pathway and de novo serine synthesis. Pyruvate can be metabolized 
to  lactate  in  the  cytosol  or  transported  into  mitochondria  via  the  pyruvate  carrier. 
Mitochondrial pyruvate can then be used for the synthesis of acetyl-CoA and citrate. Under 
certain circumstances, citrate can also be generated by reductive carboxylation of glutamine. 
Biosynthetic reactions also require reducing equivalents in the form of NADPH, which can be 
supplied by cytosolic citrate, via isocitrate dehydrogenase (IDH) and the malic enzyme (ME), 
or by the pentose phosphate pathway.  
Abbreviations: FAS –  Fatty  acid synthase,  ACC –  Acetyl-CoA  carboxylase,  ACYL  –  ATP 
Citrate lyase, ME – Malic enzyme,  IDH – Isocitrate dehydrogenase, GLS – Glutaminase, 
G6PDH – Glucose-6-phosphate dehydrogenase, PFK1 – Phosphofructokinase 1, PHGDH – 
Phosphoglycerate  dehydrogenase,  PGAM  –  Phosphoglycerate  mutase,  PK  –  Pyruvate 
kinase, LDH – Lactate dehydrogenase, PDH – Pyruvate dehydrogenase, ETC – Electron 





Figure 1.2. Nucleotide biosynthesis and the contribution of serine and glycine to one-
carbon metabolism  
Nucleotide biosynthesis requires input of carbons from tetrahydrofolate (THF), glycine, and 
phosphoribosyl  pyrophosphate  (PRPP).  Folate-derived  THF  can  be  metabolized  in  the 
cytosol or in mitochondria by the indicated enzymes. THF is converted to mTHF (methylene-
tetrahydrofolate)  in  a  cycle  that  is  coupled  to  the  conversion  of  serine  to  glycine. 
Mitochondrial glycine can also contribute to mTHF via the glycine cleavage system (GCS). 
Serine, a major one-carbon  donor  for  the  synthesis  of  mTHF,  can  be  imported  from  the 
extracellular milieu, synthesized from glycine, or from glucose-derived carbons. Glycine can 
be  generated  from  serine  or  from  threonine.  In  addition  to  nucleotide  biosynthesis,  one-
carbon  metabolism  involving  mTHF  supports  methionine  and  SAM  production  as  well  as 
NADPH synthesis.  
Abbreviations:  SHMT1  –  Serine  hydroxymethyltransferase  1,  SHMT2  –  Serine 
hydroxymethyltransferase 2, MTHFD1L – 10-formyl-tetrahydrofolate synthetase , MTHFD1 – 
Methylenetetrahydrofolate  dehydrogenase  1,  MTHFD2  –  Methylenetetrahydrofolate 
dehydrogenase 2, PSP – Phosphoserine phosphatase, TDH – Threonine dehydrogenase, 
PSAT1 – Phosphoserine aminotransferase, PHGDH – 3-Phosphoglycerate dehydrogenase, 
mTHF – Methylene-tetrahydrofolate, THF – Tetrahydrofolate, SAM – S-Adenosyl-methionine, 
G6PDH  –  Glucose-6-phosphate  dehydrogenase,  PRPP  –  Phosphoribosyl  pyrophosphate, 
GCS – Glycine cleavage system. 
! 
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In certain settings, a preferential switch to the less active PKM2 isoform over the constitutively 
active PKM1 or loss of PK activity can facilitate diversion of glycolytic intermediates to the 
PPP  and  de  novo  serine  biosynthesis  [10-12].  In  terms  of  pathway  flux,  however,  these 
metabolic  shifts  are  not  absolute,  and  a  percentage  of  PEP  can  generate  pyruvate  that 
subsequently enters the mitochondria.    
 
Meeting  the  biosynthetic  requirements  of  proliferation:  The  role  of  mitochondrial 
metabolism 
  Despite the clear importance of glycolytic intermediates for proliferation, glycolysis is 
not the only source of biosynthetic precursors for new biomass. Mitochondria make several 
important  anabolic  contributions,  including  citrate  synthesis  and  folate  metabolism.  As 
described  below,  these  are  in  turn  integrated  with  metabolism  of  a  variety  of  substrates 
including amino acids and fatty acids. 
Pyruvate,  citrate  and  de  novo  lipogenesis.  Generation  of  citrate  from  pyruvate  in 
mitochondria is dependent on both regulated mitochondrial transport of pyruvate through the 
pyruvate  carrier  and  the  activity  of  pyruvate  dehydrogenase  (PDH),  which  decarboxylates 
pyruvate to acetyl-CoA for entry into the TCA cycle (Figure 1.1). PDH activity is regulated 
through several mechanisms, including allosteric modulation and phosphorylation. Pyruvate 
dehydrogenase  kinases  (PDKs)  phosphorylate  and  inhibit  PDH,  while  pyruvate 
dehydrogenase  phosphatases  (PDPs)  remove  this  inhibitory  post-translational  modification 
[13]. Several oncogenes and oncogenic signaling pathways converge on regulation of PDH 
phosphorylation [14-18]. PDH activity is highly varied across different cancer types. In certain 
cancers,  increased  PDH  activity  may  serve  as  a  metabolic  adaptation  to  support  citrate 
synthesis [19, 20]. Citrate produced by the PDH reaction is transported to the cytosol by the 
mitochondrial citrate carrier [21], and subsequently used for de novo fatty acid synthesis, a 
chief anabolic requirement of membrane biogenesis and cellular proliferation. De novo fatty  
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acid synthesis is regulated by the coordinate function of acetyl-CoA carboxylase (ACC) and 
fatty acid synthase (FAS) (Figure 1.1). Cytosolic acetyl-CoA used for fatty acid synthesis is 
produced from citrate through the reaction catalyzed by ATP citrate lyase (ACLY) (Figure 1.1).  
Glutamine-mediated  anaplerosis.  The  lipogenic  fate  of  glucose-derived  carbons  and  the 
attendant  export  of  citrate  from  mitochondria  necessitate  replenishment  of  TCA  cycle 
intermediates (also known as anaplerosis). This is fulfilled by extracellular glutamine, which 
provides  important  anaplerotic  input  into  the  TCA  cycle  once  it  is  metabolized  through 
glutaminase  (GLS)  as  well  as  glutamate  dehydrogenase  to  produce  α-ketoglutarate  and 
ultimately  oxaloacetate  (OAA)  (Figure  1.1).  In  addition  to  anaplerotic  provision  of  OAA, 
glutamine can be used to generate NADPH through the malic enzyme reaction (ME, Figure 
1.1), providing additional reducing power for fatty acid synthesis and other anabolic reactions. 
The  coordinate  utilization  of  glucose-  and  glutamine-derived  carbons  to  ensure  fatty  acid 
synthesis is consistent with high rates of both glucose and glutamine uptake during rapid 
proliferation [22-24]. While glutaminolysis has a predominant anaplerotic role in replenishment 
of  OAA,  under  certain  nutrient  deprivation  conditions,  it  can  be  used  to  generate  citrate 
through reductive carboxylation. This involves conversion of glutamine-derived α-ketoglutarate 
to  isocitrate  by  the  reverse  reactions  of  the  NADPH  dependent  isocitrate  dehydrogenase 
(IDH)  isoforms  [25-27]  (Figure  1.1).  However,  the  physiologic  contribution  of  reductive 
carboxylation to citrate synthesis is not fully known.  
Fatty  acid  β-oxidation.  Beyond  glutamine,  other  non-glucose  mitochondrial  substrates  can 
also support cellular proliferation in a context-specific manner. Fatty acid β-oxidation (FAO) in 
the mitochondrial matrix serves as an additional source of acetyl-CoA for both ATP synthesis 
and citrate production (Figure 1.3). For example, in ovarian cancers that metastasize to the 
omental fat pad, increased mitochondrial FAO is supported by lipids supplied by neighboring 





Figure 1.3. Fatty acid oxidation and contribution to the citrate pool   
Long  chain  fatty  acids  (FAs)  are  imported  into  the  mitochondria  in  a  CPT1  dependent 
manner  after  activation  to  their  fatty  acyl-CoA  derivatives,  while  short  chain  FAs  diffuse 
across the mitochondrial membranes. They are then oxidized to acetyl-CoA units so that the 
FA chain length is reduced by two carbons in every cycle of β-oxidation. Fatty acid-derived 
acetyl-CoA units can then enter the TCA cycle and be completely oxidized to generate ATP 
through  OXPHOS  or  contribute  to  the  citrate  pool  for  export  to  the  cytosol,  de  novo 
lipogenesis and generation of NADPH for reductive potential.  
Abbreviations: ACS – Acyl-CoA synthetase, CPT1 – Carnitine palmitoyl transferase 1. Cn 




The elevated FAO observed in these cells is dependent on AMPK-mediated inhibition of ACC 
and  the  attendant  increase  in  fatty  acid  import  into  the  mitochondria  via  carnitine  palmitoyl 
transferase (CPT)1 [28] (Figure 1.3). In a 3D culture model of breast cancer, FAO provides pro-
survival benefits following matrix-detachment and loss of growth factor-mediated glucose uptake 
[29]. Increased FAO in this setting appears to be driven by the promyelocytic leukemia protein 
(PML)  in  a  PGC1α-dependent  manner.  In  this  model,  FAO-mediated  survival  under  anoikis 
ultimately allows luminal filling, which precedes breast cancer development [29]. Furthermore, 
as discussed in Chapter 2, FAO provides pro-proliferative and pro-survival benefits to a subset 
of diffuse large B-cell lymphomas (DLBCLs) [19].  
Mitochondrial  one-carbon  metabolism.  Another  important  anabolic  contribution  of 
mitochondria is made through folate-dependent one-carbon metabolism also known as the 
mitochondrial glycine biosynthetic pathway. This pathway provides a significant portion of the 
one-carbon  pool  required  for  de  novo  purine  biosynthesis  [30]  (Figure  1.2).  The  major 
reactions  of  one-carbon  metabolism  occur  in  both  the  cytosol  and  the  mitochondria  with 
limited  direct  exchange  of  folate  metabolites  between  compartments.  Mitochondrial  one-
carbon metabolism is particularly relevant for cancer cell proliferation as evident from recent 
global metabolic profiling of the NCI-60 cancer cell lines, which indicated a tight correlation 
between  proliferation  and  both  glycine  uptake  and  the  mitochondrial  glycine  biosynthetic 
pathway [31]. Consistent with this, proliferation rates across the NCI-60 panel correlated with 
the expression of three enzymes in the mitochondrial glycine biosynthetic pathway, serine 
hydroxymethyl  transferase  (SHMT)2,  methylenetetrahydrofolate  dehydrogenase  (MTHFD)1 
and  MTHFD2  (Figure  1.2),  as  opposed  to  the  expression  of  cytosolic  folate  metabolizing 
enzymes [31]. A subsequent study describing mRNA analysis of the most highly expressed 
metabolic  enzymes  across  a  large  panel  of  primary  tumors  representing  19  cancer  types 
identified MTHFD2  as a top scoring gene, which correlated with poor survival in breast cancer 
[32].   
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Two  recent  studies  have  also  uncovered  the  importance  of  mitochondrial  folate 
metabolism for NADPH production through the MTHFD2 reaction [33, 34] (Figure 1.2). NADPH 
can be generated by complete oxidation of 10-formyl-tetrahydrofolate in mitochondria to a level 
that  is  comparable  with  NADPH  produced  from  the  PPP  [34].  Accordingly,  inhibition  of 
mitochondrial  one-carbon  metabolism  following  depletion  of  MTHFD2  is  associated  with 
oxidative  stress  [34].  This  extends  the  anabolic  benefits  of  this  pathway  to  both  nucleotide 
synthesis and generation of reducing power.  
Folate  metabolism  may  be  further  integrated  with  threonine  dehydrogenase  (TDH) 
activity,  a  mitochondrial  enzyme  that  catalyzes  the  production  of  glycine  from  threonine 
(Figure 1.2). TDH activity was recently shown to be up-regulated in mouse embryonic stem 
cells  compared  with  their  differentiated  progeny  and  to  be  required  for  their  growth  and 
survival [35, 36]. Overall, the aforementioned observations underscore the relevance of the 
mitochondrial one-carbon pathway to cell growth in both non-malignant and malignant cells. 
 
Meeting the energy  and redox requirements of cell growth: The role of mitochondrial 
homeostatic mechanisms 
In  addition  to  biosynthetic  intermediates  necessary  for  generating  new  biomass, 
proliferating  cells  must  also  satisfy  energetic  demands  and  maintain  redox  balance. 
Mitochondria can directly impact these parameters as they are the main source of ATP and 
major producers of reactive oxygen species (ROS). Several homeostatic pathways converge on 
the functional quality of mitochondria in terms of energy and ROS metabolism. Among these, 
the assembly, organization, and functional fidelity of the mitochondrial electron transport chain 
(ETC) can have a profound impact on mitochondrial ATP generation and calcium buffering, as 
well as the activity of several calcium-regulated TCA cycle dehydrogenases and the capacity of 
mitochondria to metabolize fuel substrates, ultimately affecting cellular proliferation and survival.    
! 11 
The  ETC,  which  is  comprised  of  a  series  of  large  multi-subunit  protein  complexes 
housed  within  the  mitochondrial  inner  membrane,  carries  out  redox  reactions  involving  the 
transfer of electrons from NADH and FADH2 supplied by the TCA cycle. Oxygen is consumed 
during this process to provide a final electron acceptor. Electron transfer is accompanied by 
proton  extrusion  from  the  mitochondrial  matrix  to  the  inner  membrane  space,  producing  an 
electrochemical gradient. The energy stored in the protons as they flow back to the matrix is 
then used to combine inorganic phosphate with ADP to generate ATP by the enzymatic action 
of the mitochondrial ATP synthase complex.  
A functional ETC requires the proper synthesis, localization and assembly of a large 
number  of  protein  subunits  encoded  by  both  the  nuclear  and  mitochondrial  genomes.  This 
requires  transcription  and  translation  of  mitochondrial  DNA  (mtDNA)-encoded  genes  by  a 
dedicated  mitochondrial  translation  machinery  independent  of  the  pathway  in  charge  of 
translating mRNAs encoded by the nuclear genome [37]. In addition, a host of chaperones and 
proteases exist to ensure proper folding and assembly of ETC complexes, as well as to clear 
excess  or  misfolded  components.  For  example,  the  inner  membrane  m-AAA  and  i-AAA 
proteases are central to degrading unassembled or damaged ETC complexes, and their loss of 
function  is  associated  with  profound  ETC  defects  in  several  human  pathologies  [38-40].  In 
addition  to  proper  assembly  of  subunits  within  ETC  complexes,  the  organization  of  ETC 
complexes  into  supercomplexes  has  been  shown  to  impact  mitochondrial  bioenergetics.  In 
particular, dynamic assembly of ETC complexes I, III and IV into supercomplexes was shown to 
be tightly integrated with the pattern and kinetics of electron flow through the ETC, ultimately 
influencing  the  efficiency  of  carbon  substrate  oxidation  [41].  In  addition,  the  assembly  and 
organization of ETC complexes is integrated with mitochondrial morphology and dynamics [42]. 
  Mitochondria are also a major source of cellular ROS generated by incomplete reduction 
of oxygen due to electron slippage, predominantly from respiratory chain complexes I and III 
[43-45]. Low levels of ROS, particularly hydrogen peroxide (H2O2), can be important for pro- 
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proliferative signals. For example, certain KRAS-driven cancer cells require mitochondrial ROS 
for proliferation, suggesting that mitochondrial redox signaling can support oncogenic growth 
pathways  [46].  However,  excessive  ROS  can  cause  irreversible  damage  to  cellular  lipids, 
proteins and DNA and push cells towards apoptosis. Mitochondria are particularly susceptible to 
such damage due to the higher probability of H2O2 reacting with iron-containing complexes in 
the  mitochondrial  inner  membrane  and  matrix.  Several  mechanisms  are  in  place  to  keep 
mitochondrial ROS in check through modulation of ROS production as well as ROS clearance. 
In particular, mitophagy has emerged as an important homeostatic pathway of mitochondrial 
quality control, whereby damaged mitochondria or mitochondria that produce high levels of ROS 
due to inefficient ETC function, are cleared from the mitochondrial network [47].  
  The aforementioned pathways are but a few examples of a diverse and complex array of 
homeostatic mechanisms evolved to ensure the functional fidelity of mitochondrial substrate and 
energy  metabolism.  As  such,  they  can  indirectly  influence  cellular  proliferation,  survival  and 
stress responses. 
 
Metabolic heterogeneity in the context of cancer and an overview of this dissertation 
Significant  progress  has  been  made  in  our  understanding  of  how  aerobic  glycolysis 
contributes  to  proliferation  and  underlying  signaling  pathways.  However,  the  universal 
applicability of these findings to all proliferating cell types has not been established and, in fact, 
as discussed above, there is substantial evidence to suggest that other metabolic pathways also 
make important contributions to proliferation in a cell type- and context-dependent manner. The 
diversity and complexity of metabolic solutions to meeting the biosynthetic and bioenergetic 
requirements of cell growth is also reflected by the heterogeneity of metabolic programs that 
provide  pro-proliferative  and  pro-survival  advantages  to  cancer  cells.  Understanding  this 
heterogeneity  at  the  molecular  level  requires  a  detailed  dissection  of  metabolic  circuits  and 
associated dependencies on fuel utilization and biosynthetic pathways of individual tumor types.  
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This  will  ultimately  facilitate  the  development  of  therapies  tailored  to  specific  metabolic 
vulnerabilities in the relevant tumor types. 
The heterogeneity of metabolic fingerprints in tumors may be relevant, not only across 
different  cancers,  but  also  within  distinct  subtypes  of  heterogeneous  tumors  that  otherwise 
share a common initial diagnosis. The following chapters describe the integrative dissection of 
metabolic  circuits  in  one  of  the  most  heterogeneous  types  of  cancer,  Diffuse  Large  B-cell 
Lymphoma (DLBCL), which uncovered distinct patterns of nutrient and energy metabolism and 
associated  targetable  dependencies  in  separate  molecular  subtypes  of  DLBCL.  Chapter  2 
investigates  the  metabolic  attributes  of  OxPhos-DLBCLs,  a  molecular  subset  of  DLBCL 
previously  shown  to  be  genetically  distinct  from  B-cell  receptor  (BCR)-dependent  DLBCLs 
(BCR-DLBCLs). OxPhos-DLBCLs do not require a functional BCR, which normally promotes the 
survival  of  BCR-DLBCLs  through  a  PI3K-dependent  mechanism  [48,  49].  They  also  display 
increased  expression  of  mitochondrial  oxidative  phosphorylation  genes  [50].  However,  the 
functional  attributes  OxPhos-DLBCLs  and  the  nature  of  their  BCR-independent  survival 
mechanisms was not known. This investigation identified clear differences in glucose and fatty 
acid  metabolism,  as  well  as  mitochondrial  ETC  activity  among  the  two  DLBCL  subtypes. 
Specifically, BCR-DLBCLs have greater glycolytic flux typical of the Warburg phenotype. Unlike 
BCR-DLBCLs,  OxPhos-DLBCLs  channel  the  majority  of  glucose-derived  pyruvate  into 
mitochondria,  display  elevated  mitochondrial  ETC  activity,  ATP  production,  and  FAO. 
Importantly,  these  metabolic  distinctions  are  associated  with  subtype-selective  survival 
mechanisms  and  predictable  vulnerabilities.  Chapter  3  characterizes  the  contribution  of  the 
mitochondrial translation pathway to the metabolic phenotype of OxPhos-DLBCLs and provides 
evidence for its pro-survival benefits selective to OxPhos- but not Warburg-type/BCR-DLBCLs. 
Chapter 4 identifies alterations in mitochondrial morphology and network architecture that are 
required  for  increased  FAO  in  OxPhos-DLBCLs  without  affecting  mitochondrial  oxidation  of 
other  substrates.  In  summary,  the  findings  described  in  the  following  chapters  demonstrate  
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previously unappreciated metabolic heterogeneity in molecular subsets of DLBCLs and uncover 
BCR-independent survival mechanisms that are linked to mitochondrial FAO, protein translation 
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Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of                        




Molecular signatures have identified several subsets of Diffuse Large B-cell Lymphoma 
(DLBCL)  and  rational  targets  within  the  B-cell  receptor  (BCR)  signaling  axis.  The  OxPhos-
DLBCL subset, which harbors the signature of genes involved in mitochondrial metabolism, is 
insensitive to inhibition of BCR survival signaling, but is functionally undefined. We show that 
compared  with  BCR-DLBCLs,  OxPhos-DLBCLs  display  enhanced  mitochondrial  energy 
transduction, greater incorporation of nutrient-derived carbons into the TCA cycle and increased 
glutathione levels. Importantly, perturbation of the fatty acid oxidation program and glutathione 
synthesis  proved  selectively  toxic  to  this  tumor  subset.  Our  analysis  provides  evidence  for 
distinct metabolic fingerprints and associated survival mechanisms in DLBCL and may have 


















Tumors  often  rewire  their  metabolism  to  ensure  a  steady  supply  of  intermediary 
metabolites  for  synthesis  of  new  biomass,  as  well  as  generation  of  ATP  and  reducing 
equivalents [1-3]. This metabolic reprogramming is a dynamic process shaped by oncogenes 
and tumor suppressors [1, 4, 5]. One of the first metabolic alterations identified in tumors is 
elevated glycolysis even in the presence of sufficient oxygen. This program, also known as the 
Warburg effect or aerobic glycolysis, fulfills important biosynthetic needs [1, 6, 7]. The Warburg 
effect  has  often  been  interpreted  as  an  indication  of  impaired  mitochondrial  respiration  [6]. 
However, the relevance of mitochondrial respiration in tumors is varied depending on tumor 
type, and evidence for an oxidative class of tumors and tumors with dual capacity for glycolytic 
and oxidative metabolism exists [8, 9]. Moreover, the importance of mitochondria in tumor cell 
survival  and  proliferation,  including  utilization  of  alternative  oxidizable  substrates  such  as 
glutamine and fatty acids has been increasingly appreciated [10-12]. The diversity of carbon 
substrate utilization pathways in tumors is indicative of metabolic heterogeneity that may not 
only be relevant across different types of cancer but also manifest within a group of tumors that 
otherwise share a common diagnosis.  
Diffuse Large B-cell Lymphomas (DLBCLs) are a genetically heterogeneous group of 
tumors  and  the  most  common  non-Hodgkin  lymphomas  in  adults  [13,  14].  However,  the 
spectrum of fuel utilization pathways and the metabolic fingerprints within DLBCL and other 
similarly heterogeneous groups of tumors have not been fully elucidated. To date, efforts to 
capture the molecular heterogeneity of DLBCL have relied on gene expression profiling that has 
uncovered coordinate signaling and survival paradigms in distinct subsets of DLBCL. In one 
approach, comparison of the genetic signatures across DLBCLs using genome-wide arrays and 
multiple  clustering  algorithms  captured  tumor-intrinsic  distinctions  in  three  separate  and 











Figure 2.1. Schematic illustration of OxPhos- and BCR-DLBCL subsets identified by 
consensus cluster classification  
Graphics are courtesy of Eric Smith. 
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Groups of DLBCLs identified by this consensus cluster classification (CCC) scheme are the 
BCR/proliferation  cluster  (BCR-DLBCL)  displaying  up-regulation  of  genes  encoding  B-cell 
receptor  (BCR)  signaling  components,  the  OxPhos  cluster  (OxPhos-DLBCL),  which  is 
significantly  enriched  in  genes  involved  in  mitochondrial  oxidative  phosphorylation  (OxPhos) 
(Figure  2.1),  and  the  host  response  (HR)  tumors  largely  characterized  by  a  brisk  host 
inflammatory  infiltrate  [15].  Another  classification  framework  known  as  cell-of-origin  (COO) 
delineated DLBCL subsets that shared components of their transcriptional profiles with normal 
B-cell subtypes, including Germinal Center B-cell (GCB)-like  and  Activated  B-cell (ABC)-like 
[16], and a third undefined category, designated “type 3” [17]. CCC and COO classifications 
capture largely different molecular aspects of DLBCL [15]. 
Unlike  tumors  that  rely  on  signaling  pathways  downstream  of  the  B-cell  receptor, 
OxPhos-DLBCLs do not display active/functional BCR signaling [18]. However, the nature of 
survival  pathways  in  this  group  of  tumors  is  not  known  and  beyond  the  original  CCC 
assignment, the actual functional attributes of the OxPhos molecular signature have not been 
fully  examined.  This  signature  includes  multiple  subunits  of  mitochondrial  respiratory  chain 
complexes I (NADH dehydrogenase) and V (mitochondrial ATP synthase) that may suggest 
alterations  in  mitochondrial  energy  transduction.  However,  given  the  integrative  aspect  of 
cellular metabolism and the requirement of both nuclear and mitochondria-encoded genes for 
proper functioning of the electron transport machinery, the precise metabolic landscape of this 
molecular subset could not be predicted.  
In  the  present  study,  we  conducted  an  integrative  analysis  to  dissect  the  metabolic 
fingerprints  of  DLBCL  and  to  delineate  subtype-specific  differences  that  may  selectively 






Subtype-specific differences in the DLBCL mitochondrial proteome  
The up-regulation of select genes encoding for subunits of electron transport chain (ETC) 
complexes  in  OxPhos-DLBCLs  predicts  potential  differences  in  mitochondrial  oxidative 
metabolism  compared  with  other  DLBCL  groups.  However,  as  ETC  activity  is  linked  to  the 
supply of carbon substrates and reducing equivalents, the OxPhos signature is likely part of a 
broader spectrum of changes in mitochondrial nutrient metabolism that may shed light on the 
actual  functional  attributes  of  an  “OxPhos”  program  in  this  DLBCL  subset.  To  search  for 
additional  components  of  this  metabolic  program,  we  initially  performed  two  dimensional 
differential  gel  electrophoresis  (2D-DIGE)  to  compare  the  proteome  of  mitochondria  purified 
from representative OxPhos- and BCR-DLBCL cell lines Karpas 422 and OCI-Ly1, respectively 
[18]. Mitochondrial proteins that were ≥ 2.5 fold more abundant in the OxPhos cell line were 
identified by mass spectrometry (Figure 2-S1). Among 2D-DIGE candidates were subunits of 
mitochondrial  respiratory  chain  complex  I  (NADH  dehydrogenase),  complex  II  (succinate 
dehydrogenase,  also  a  TCA  cycle  enzyme),  complex  V  (ATP  synthase),  subunits  of  the 
pyruvate dehydrogenase (PDH) complex and several other TCA cycle enzymes, mitochondrial 
ROS detoxification enzyme manganese superoxide dismutase (MnSOD or SOD2), as well as 
enzymes involved in mitochondrial β-oxidation of fatty acids and metabolism of ketone bodies 
and amino acids (Figure 2-S1). 
We next wished to interrogate the mitochondrial protein signature defined by 2D-DIGE in a 
larger panel of OxPhos- and BCR-DLBCL cell lines. This required an independent proteomics 
approach  amenable  to  multiplexing-  isobaric  tags  for  relative  and  absolute  quantification 
(iTRAQ)  (Figure  2-S2)  [19,  20]  for  simultaneous  quantitative  comparison  of  multiple  unique 
tryptic peptides per candidate mitochondrial protein across three pairs of OxPhos- and BCR-























Figure 2.2. Comparison of mitochondrial proteome in OxPhos- and BCR-DLBCLs 
(A and B) Multiplex iTRAQ analysis of mitochondria derived from three OxPhos- (Karpas 
422, Toledo, and Pfeiffer) and three BCR- (OCI-Ly1, SU-DHL-4, and SU-DHL-6) DLBCL cell 
lines. Log-log plots of reporter ions abundance ratios vs. reporter ion intensities for proteins 
detected  in  replicate  nanoflow  LC-MS/MS  analyses  are  shown  (A).  Proteins  within  the 
mitochondrial signature that are enriched in OxPhos-DLBCLs are shown as red circles in (A) 
and  grouped  per  metabolic  pathway  in  (B).  Red  lines  in  (A)  represent  global  thresholds 





























This  analysis  confirmed  significant  quantitative  enrichment  of  mitochondrial  β-oxidation 
enzymes, multiple subunits of respiratory chain complexes, as well as TCA cycle enzymes and 
MnSOD in OxPhos-DLBCL mitochondria (Figure 2.2 and Table 2.1).  
Beyond confirming the differential expression of complex I and V components that were in 
the original OxPhos-DLBCL cluster signature [15], the 2D-DIGE and iTRAQ proteomic analyses 
identified additional components of the OxPhos-DLBCL mitochondrial signature that were not 
fully captured by the previous RNA profile analysis of total tumors. To examine whether these 
observations  could  also  be  substantiated  in  primary  OxPhos-DLBCLs,  we  examined  tumor 
biopsies  for  differences  in  the  abundance  of  these  newly  identified  components  of  the 
mitochondrial  signature  at  both  protein  and  RNA  levels.  The  small  en  bloc  primary  DLBCL 
biopsies precluded isolation of tumor mitochondria; however, iTRAQ-based quantification in a 
limited number of primary cases that produced protein samples of suitable purity and grade for 
LC-MS/MS indicated increased expression of several TCA cycle and mitochondrial β-oxidation 
enzymes, as well as MnSOD (Table 2.1). The RNA abundance for candidate components of the 
mitochondrial proteome signature was also queried in two extensive primary DLBCL expression 
profile  data  sets  [15,  21]  with  CCC  designations  (Tables  2-S1  and  2-S2)  and  found  to  be 
significantly higher in primary OxPhos- than in BCR-DLBCLs in both data sets (Figure 2.3). 
These observations confirm that the differences in mitochondrial signature identified in DLBCL 
cell lines translate to primary tumor biopsies.  
The  functional  categories  of  proteins  in  the  OxPhos-DLBCL  mitochondrial  signature 
predict  differences  in  mitochondrial  handling  of  fatty  acids  and  pyruvate,  ETC  activity, 



















Figure  2.3.  Increased  abundance  of  transcripts  encoding  mitochondrial  proteins  in 
primary DLBCL tumor biopsies 
(A)  Heat  map  representation  of  the  relative  mRNA  levels  of  genes  corresponding  to  the 
components of the mitochondrial proteome signature using the Monti et al. (left) and Lenz et al. 
(right) expression array data sets of primary DLBCL cases with OxPhos and BCR consensus 
cluster assignments. (B) Transcript abundance (probe intensity) of the indicated genes in primary 
OxPhos-  and  BCR-  DLBCLs  from  the  Monti  et  al.  (top)  and  Lenz  et  al.  (bottom)  data  sets. 
Differential expression was determined by a two-sided Mann Whitney test and p values were 
corrected  for  multiple  hypothesis  testing  using  the  false  discovery  rate  (FDR)  procedure. 
Abbreviations: PDH – pyruvate dehydrogenase; NDUFA5 – NADH dehydrogenase (ubiquinone) 
1α subcomplex subunit 5; NDUFS3 – NADH dehydrogenase (ubiquinone) Fe-S protein 3; ETF –  
electron-transfer-flavoprotein;  ACAT  –  acetoacetyl-CoA  thiolase;  MTHFD2  –  
methylenetetrahydrofolate dehydrogenase 2; SOD2 – manganese superoxide dismutase. 
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Mitochondrial substrate oxidation in DLBCL subsets 
To  assess  potential  differences  in  mitochondrial  carbon  substrate  utilization, 
mitochondrial oxygen consumption rate (OCR) was measured in real time in the absence or 
presence of exogenously added substrates such as glucose, glutamine or palmitate using a 
panel of 3-4 independent OxPhos and “non-OxPhos” DLBCL cell lines. The “non-OxPhos” panel 
included cell lines with known CCC assignment as BCR-DLBCLs [22] and COO classification as 
GCB-, ABC-, or Type 3-DLBCLs [16, 17] (Table 2.2). Basal OCR in response to exogenously 
supplied palmitate was significantly higher in OxPhos-DLBCLs relative to “non-OxPhos” DLBCL 
cell  lines  [no  substrate  (NS)  vs.  palmitate  (Figure  2.4A)].  Basal  OCR  values  per  individual 
DLBCL cell line are shown in Figure 2-S3.  The “non-OxPhos” DLBCLs displayed either no 
increase in OCR or an increase that was significantly less than that observed in the OxPhos-
DLBCLs  (Figures  2.4A  and  2-S3).  Importantly,  the  majority  of  palmitate-stimulated  OCR  in 
OxPhos-DLBCLs  was  sensitive  to  the  mitochondrial  ATP  synthase  inhibitor  oligomycin, 
indicating that mitochondrial fatty acid oxidation (FAO) in this setting is associated with ATP 
synthesis  (Figures  2.4A  and  2-S3).  These  observations  provide  quantitative  evidence  for 
increased  mitochondrial  FAO  in  OxPhos-DLBCLs.  Analysis  of  other  oxidizable  substrates 
showed that none of the DLBCL subsets respire on glucose (NS vs. glucose, Figures 2.4A and 
2-S3). However, in response to glutamine, all DLBCL subsets exhibited a comparable increase 
in basal and ATP-associated (oligomycin inhibitable) OCR (NS vs. glutamine, Figures 2.4A and 
2-S3). Taken together, comparison of the three carbon substrates across and within DLBCL 
subsets indicates that palmitate is a predominant respiratory fuel in OxPhos-DLBCLs.   
A marked increase in palmitate-induced OCR in OxPhos-DLBCL compared with “non-
OxPhos” DLBCL cell lines parallels the absence or presence of functional BCR signaling in 
these  subsets,  respectively  [18].  This  prompted  examination  of  a  potential  reciprocal 













Table 2.2.  CC  and  COO  classification  assignments  for  DLBCL  cell  lines  used  in this 
study 
Cell Line  Classification 
  CC  COO 
SU-DHL-4  BCR  GCB 
SU-DHL-6  BCR  GCB 
OCI-Ly1  BCR  GCB 
OCI-Ly7  BCR  Type 3 
     
Karpas 422  OxPhos  GCB 
OCI-Ly4  OxPhos  Type 3 
Pfeiffer  OxPhos  Type 3 
Toledo  OxPhos  Type 3 
     
OCI-Ly3  BCR  ABC 
OCI-Ly10  BCR  ABC 
HBL-1  BCR  ABC 
U2932  BCR  ABC 
!
Consensus cluster (CC) and Cell type of origin (COO) classifications for the indicated cell lines 








Figure  2.4.  Mitochondrial  carbon  substrate  oxidation  in  DLBCL  subsets  and  its 
regulation by BCR signaling 
(A) Basal (left) and ATP-coupled (right) OCR in DLBCL subsets. OCR values shown are 
average  of  all  cell  lines  per  DLBCL  subtype  indicated  on  top.  For  each  cell  line,  7-13 
independent OCR measurements were taken. NS denotes no substrate added exogenously. 
(B)  Palmitate-stimulated  basal  OCR  in  “non-OxPhos”  DLBCL  cell  lines  after  acute 
knockdown  of  SYK.  Error  bars,  ±  SEM.  *p  <  0.05;  **p  <  0.01;  ***p  <  0.001;  two-tailed 
Student’s t-test.  
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Such a scenario would predict that inhibition of BCR signaling in non-OxPhos/BCR DLBCLs 
may manifest in increased mitochondrial FAO. Indeed, acute interference with BCR signaling 
using  multiple  independent  shRNAs  against  SYK  or  CD79B,  upstream  components  of  this 
signaling  axis,  was  associated  with  significant  elevation  of  basal  palmitate-induced  OCR 
(Figures 2.4B and 2-S4). Notably, OCR measurements were taken after 24 hr treatment with 
shRNAs,  which  enabled  sufficient  depletion  of  SYK  and  CD79B  (Figure  2-S5  and  data  not 
shown)  without  affecting  cell  viability  (data  not  shown).  These  observations  suggest  an 
underlying metabolic plasticity that governs the pattern of fuel oxidation in DLBCL subsets. 
To provide independent and parallel evidence for differential utilization of fatty acids in 
DLBCL subsets, a targeted 
13C isotopomer approach was undertaken. A total of eight cell lines 
with known designation as OxPhos or BCR were cultured in media containing uniformly labeled 
13C-palmitate  (U
13C-palmitate),  and 
13C  enrichment  was  assessed  in  a  defined  set  of 
intermediates derived from fatty acid metabolism. The complete oxidation of 
13C-palmitate by 
mitochondria yields 8 acetyl units that can donate carbons to the TCA cycle in the form of citrate 
labeled  on  two  carbons  (
13C2-citrate),  which  can  in  turn  lead  to  the  formation  of 
13C2-α-
ketoglutarate that is in isotopic equilibrium with 
13C2-glutamate (Figure 2.5A). The relative level 
of 
13C  enrichment  in  both 
13C2-citrate  and 
13C2-glutamate  was  significantly  higher  in  the 
OxPhos-DLBCL  cell  lines  (Figure  2.5B).  This  is  consistent  with  greater  entry  of  palmitate 
carbons into the TCA cycle.  
In addition to oxidative metabolism for energy production, palmitate may have important 
biosynthetic roles, including direct incorporation into phosphatidyl choline (PC) to yield U
13C-
Palmitate-PC  (Figure  2.5A).  Alternatively,  palmitate-derived  citrate  can  be  exported  from 
mitochondria and its carbons subsequently incorporated into the head group of PC (
13C2-Acetyl-
PC, Figure 2.5A). In both DLBCL subtypes, direct incorporation of palmitate into PC (U
13C-
Palmitate-PC)  was  observed.  In  addition,  a  larger  enrichment  of  palmitate  carbons  in 
13C2-













Figure 2.5. Differential fate of palmitate-derived carbons in DLBCL subsets 
(A  and  B) 
13C  isotopomer  analysis  of  uniformly  labeled  palmitate  (U
13C-Palmitate).  (A) 
Schematics  depicting  the  number  of  carbons  labeled  (filled  circles)  in  a  defined  set  of 
metabolites derived from palmitate. Metabolites marked in red are selectively elevated in 
OxPhos-DLBCL cell lines. (B) 
13C enrichment in palmitate-derived metabolites. For each 
metabolite,  cumulative  data  obtained  from  all  four OxPhos-DLBCL  cell  lines  are  shown 
relative to the mean value of that metabolite in all four BCR-DLBCL cell lines listed on top. 

























Figure 2.6. Effect of palmitate metabolism on DLBCL proliferation and survival 
(A)  Effect  of  palmitate  supplementation  on  the  proliferation  of  DLBCL  cell  lines.  Control 
denotes serum-free media containing all amino acids except L-glutamine. (B) Effects of acute 
bromocrotonic  acid  treatment  on  palmitate-stimulated  basal  OCR  in  DLBCL  cell  lines.  The 
indicated cell lines were treated with 7.5 µM bromocrotonic acid (BrCA) for 4 hr and basal OCR 
was measured in response to palmitate as the only exogenously added substrate. (C) Survival 
of DLBCL subsets cultured in the absence or presence of BrCA for 24 hr. Error bars, ± SEM. 






Figure 2.6. (continued)  
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A preferential increase in palmitate utilization in OxPhos-DLBCLs prompted examination 
of  its  effect  on  proliferation  in  these  cells.  Supplementation  of  serum-free  media  containing 
amino acids with palmitate and carnitine led to a modest but significant and selective increase in 
the proliferation of OxPhos-DLBCLs (Figure 2.6A). In the absence of palmitate, carnitine, which 
is  required  for  mitochondrial  import  of  long-chain  fatty  acids,  did  not  influence  proliferation 
(Figure 2.6A).  
To probe the pro-survival benefit of mitochondrial FAO in DLBCL subsets, this program 
was  inhibited  using  4-bromocrotonic  acid  (BrCA),  which  irreversibly  inhibits  mitochondrial            
β-oxidation of both long- and short-chain fatty acids [23]. Acute treatment of DLBCL cell lines   
(4 hr) with BrCA interfered with palmitate stimulation of basal OCR in OxPhos-DLBCL cell lines 
(Figure 2.6B), while longer treatment (24 hr) was selectively toxic to this subset compared with 
BCR-DLBCLs  (Figure  2.6C).  These  results  suggest  that  the  mitochondrial  FAO  program 
provides pro-survival benefits to OxPhos-DLBCLs.  
 
Programmatic  regulation  of  Fatty  Acid  Oxidation  and  its  relevance  to  OxPhos-DLBCL 
survival  
The concomitant increase in the abundance of several mitochondrial FAO enzymes in 
OxPhos-DLBCLs  is  consistent,  at  least  in  part,  with  a  programmatic  increase  in  the 
transcriptional  regulation  of  this  pathway.  These  observations  warranted  systematic 
interrogation of the primary DLBCL transcript data sets for the prevalence of a defined list of 
transcriptional  regulators  of  this  pathway.  Nuclear  receptor  peroxisome  proliferator-activated 
receptor (PPAR) γ transcripts were found to be significantly more abundant in primary OxPhos-



























Figure 2.7. Programmatic regulation of FAO and its relevance to DLBCL survival 
(A) Increased transcript abundance of PPARγ in the Monti et al. (left) and Lenz et al. (right) 
data sets of primary DLBCL cases with OxPhos and BCR consensus cluster assignments. 
Differential expression was determined by a two-sided Mann Whitney test and p-values were 
corrected for multiple hypothesis testing using the false discovery rate (FDR) procedure. (B) 
Effect of siRNA-mediated depletion of PPARγ on the survival of DLBCL subsets. (C and D) 
Survival of the indicated DLBCL cell lines cultured in the absence or presence of increasing 
concentrations of PPARγ antagonists (C) T0070907 or (D) GW9662 for 96 hr. Error bars,      









Importantly,  several  enzymes  identified  in  the  mitochondrial  protein  signature  of  OxPhos-
DLBCLs  such  as  ETF,  ACAD  and  HADH,  as  well  as  multiple  subunits  of  mitochondrial 
respiratory chain complexes I, II, and ATP synthase are downstream targets of PPARγ [24]. To 
probe the functional relevance of PPARγ in DLBCL subsets, we tested the effect of its depletion 
using three independent siRNAs and their corresponding mixture (Figures 2.7B and 2-S6A). 
The most robust decrease in PPARγ protein levels was achieved using the siRNA mix (Figure  
2-S6B) and was accompanied by significant apoptosis in OxPhos-DLBCLs compared with the 
BCR subset (Figure 2.7B).  
To provide a pharmacologic correlate to these findings, we also tested the effect of two 
selective PPARγ antagonists T0070907 and GW9662 [25, 26]. Short term treatment of DLBCL 
cell lines with these compounds blocked palmitate stimulation of OCR (data not shown). Upon 
longer incubation periods (96 hr), these compounds proved selectively toxic to OxPhos-DLBCLs 
(Figures 2.7C and 2.7D). The above genetic and pharmacologic approaches to PPARγ inhibition 
complement and extend the results shown in Figure 2.6C that pharmacologic inhibition of the 
mitochondrial β-oxidation program is toxic to OxPhos-DLBCLs, and are collectively congruent 
with the idea that a sustained mitochondrial FAO program may be relevant for the survival of 
OxPhos-DLBCLs.  
 
Differential utilization of glucose-derived carbons in DLBCL subsets   
Identification  of  PDH  as  a  component  of  the  mitochondrial  proteome  signature  in  OxPhos-
DLBCLs predicts differential mitochondrial handling of pyruvate. Indeed, biochemical analysis of 
isolated mitochondria derived from a panel of DLBCL cell lines indicated a significant increase in 
PDH enzyme activity in OxPhos-DLBCLs (Figure 2.8A). Increased PDH activity would further 
predict  diminished  availability  of  glucose-derived  pyruvate  for  lactate  synthesis.  Biochemical 
quantification of glucose-derived lactate, secreted by OxPhos-DLBCL cell lines compared to  
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“non-OxPhos”/BCR counterparts, indicated that this is indeed the case (Figure 2.8A). These 
observations prompted a more detailed examination of the fate of glucose carbons in DLBCL 
subsets.   
Beyond  generation  of  pyruvate,  glucose-derived  metabolites  are  central  to  several 
biosynthetic pathways (Figures 1.1 and 2.8B). For example, glucose-6-phosphate can enter the 
pentose  phosphate  pathway  to  yield  ribose  sugars  for  nucleic  acid  synthesis  and  NADPH 
generation for lipid synthesis and ROS detoxification [3, 7]. Dihydroxyacetone phosphate, which 
is  in  equilibrium  with  glyceraldehyde-3-phosphate,  is  used  in  glycerol  synthesis,  providing  a 
necessary  backbone  for  membrane  phospholipids.  Finally,  glucose-derived  citrate  and 
aspartate, a surrogate for oxaloacetate (OAA), can be used in lipid and nucleotide synthesis, 
respectively. To examine differences in the terminal fate of glucose-derived pyruvate and the 
branch  points  at  which  glucose  carbons  divert  to  biosynthetic  pathways  in  different  DLBCL 
subsets, we carried out a targeted 




Glucose uptake was comparable in DLBCL cell lines as evident from the similar levels of 
remaining U
13C-glucose in the media following 8 hr incubation (Figure 2.8C). The BCR cell lines 
displayed a larger contribution of glucose-derived carbons to the synthesis of pentose sugars 
compared  with  the  OxPhos  cell  lines  (U
13C-pentose,  Figure  2.8C).  This  is  consistent  with 
reduced levels of U
13C-glucose-6-phosphate precursor observed in this subset (Figure 2.8C), 
provided  that  the  oxidative  branch  of  the  pentose  phosphate  pathway  is  utilized  to  derive 
pentose sugars. In addition, the contribution of glucose carbons to glycerol incorporation into PC 
was significantly higher in BCR cell lines (
13C-glycerol-PC, Figure 2.8C).  
The  overall  glycolytic  capacity  was  assessed  by  comparing  both  intracellular  and 
extracellular (secreted) U
13C-lactate and U
13C-alanine (a surrogate for pyruvate). BCR cell lines 
had significantly higher intracellular and secreted U
13C-alanine and U
























Figure 2.8. Utilization of glucose-derived carbons in DLBCL subsets 
(A) PDH enzyme activity (top) and lactate production from glucose (bottom) in DLBCL subsets. 
Data are cumulative from independent DLBCL cell lines listed on top. (B-C) 
13C isotopomer 
analysis of uniformly labeled glucose (U
13C-glucose). (B) Schematics depicting the number of 
carbons  labeled  (filled  circles)  in  intermediary  metabolites  of  glucose  metabolism.  (C)           
13C enrichment in glucose-derived metabolites. For each metabolite, cumulative data obtained 
from all four OxPhos-DLBCL cell lines (Karpas 422, OCI-Ly4, Pfeiffer and Toledo; red bars) 
are shown relative to the mean value of that metabolite in all four BCR-DLBCL cell lines (SU-
DHL-4,  SU-DHL-6,  OCI-Ly1  and  OCI-Ly7;  black  bars).  Error  bars,  ±  SEM.  *p  <  0.05;             







Figure 2.8. (continued)  
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These data are consistent with biochemical evidence that glucose-derived lactate is higher in 
these cells (Figure 2.8A), suggesting a higher glycolytic flux.  
Glucose-derived pyruvate can enter the TCA cycle through a PDH-catalyzed reaction 
yielding  citrate  or  through  a  pyruvate  carboxylase  (PC)-mediated  anaplerotic  reaction  that 
generates  OAA  [27].  The  ratio  of  PDH  and  PC  activities  in  tumors  is  variable  [27,  28], 
suggesting significant diversity and tumor type specificity in the mode of TCA cycle entry of 
glucose-derived carbons. The PDH reaction can be traced by the pattern of carbon labeling in 
citrate as 
13C2-citrate. The relative 
13C enrichment in this metabolite was significantly higher in 
OxPhos cell lines (Figure 2.8C), indicating a greater overall diversion of glucose carbons to the 
TCA cycle. Elevated PDH-catalyzed formation of 
13C2-citrate in OxPhos-DLBCLs is consistent 
with  increased  levels  of  PDH  and  enzyme  activity  in  this  subset.  Among  other  TCA  cycle 
intermediates measured in this analysis, 
13C enrichment in aspartate (surrogate for OAA) was 
relatively higher in OxPhos compared with BCR cell lines (
13C2-asparate, Figure 2.8C).  
Despite  elevated  PDH  activity  in  OxPhos-DLBCLs  and  higher  enrichment  of  glucose 
carbons  in  the  aforementioned  TCA  cycle  intermediates,  glucose  is  not  fully  oxidized  to 
stimulate mitochondrial OCR in these cells (Figures 2.4A and 2-S3). This may be due to greater 
diversion of glucose-derived TCA intermediates to biosynthetic pathways. Overall, the distinct 
enrichment patterns of carbons in glucose-derived metabolites indicate relative diminution of 
lactate production in OxPhos-DLBCL and an attendant increase in the entry of glucose carbons 
in the TCA cycle via citrate.  
 
Contribution of mitochondrial metabolism to cellular ATP budget in DLBCL subsets  
The observed differences in utilization of palmitate- and glucose-derived carbons as well 
as ATP generation through mitochondrial oxidation of palmitate (ATP-coupled respiration) in 
DLBCL subsets warranted comparison of mitochondrial and non-mitochondrial contributions to 




















Figure  2.9.  Contribution  of  mitochondrial  metabolism  to  cellular  ATP  and  energy 
transduction in DLBCL subsets 
(A) Percent contribution of glycolysis and mitochondrial metabolism to total cellular ATP. For 
each subtype, cumulative data from four OxPhos-DLBCL (Karpas 422, OCI-Ly4, Pfeiffer, and 
Toledo) and four BCR-DLBCL (SU-DHL-4, SU-DHL-6, OCI-Ly1, and OCI-Ly7) cell lines are 
shown. (B) Mitochondrial ATP synthesis rate. Cumulative data from four OxPhos-DLBCL (red 
bar)  and  four  BCR-DLBCL  (black  bar)  cell  lines  are  shown  as  in  (A).  (C)  Average copy 
number of 110 mitochondrial SNP probes for 39 primary OxPhos-DLBCL and 33 primary 
BCR-DLBCL cases. Differences were tested using a Man-Whitney U-test and found to be 
non-significant.  (D-F)  OCR  in  isolated  mitochondria  in  different  respiratory  states.  (D) 
Schematics of mitochondrial respiratory complexes and substrates as well as mitochondrial 
inhibitors  used  to  measure  their  specific  activities.  (E)  Representative  OCR  traces  in 
mitochondria isolated from DLBCL cell lines indicating respiratory states examined. (F) OCR 
in isolated mitochondria measured using complex I- or complex II-linked substrates. Data are 
derived from four cell lines per DLBCL subset listed on top. Error bars in A, B and F, ± SEM. 











Figure 2.10. Mitochondrial content and electron transport chain activity in DLBCL cell 
lines  
(A) Mitochondrial content in DLBCL cell lines measured using MitoTracker Red. Values per 
individual cell line (left) and cumulative average per subtype (right) are shown. (B) Activity of 
respiratory chain complexes I (NADH dehydrogenase), II (succinate dehydrogenase) and IV 
(cytochrome c oxidase) in mitochondria isolated from four independent DLBCL cell lines per 
subtype (listed on top) using immune-capture-based enzyme activity assays (MitoScience, 
Eugene, OR). The amount of mitochondria used was 100 µg for complexes I and IV and     
10  µg  for  complex  II  activity  measurements.  Data  show  cumulative  values  from  4-8 
independent experiments with 3-4 replicates for each cell line. Error bars, ± SEM. ns, non-




To this end, the portion of total cellular ATP that is sensitive to inhibition of glycolysis versus 
mitochondrial metabolism was assessed [29]. Compared to BCR-DLBCLs, the OxPhos subset 
derives  a  significantly  higher  portion  of  its  total  energy  (~70%)  from  mitochondrial  oxidative 
metabolism than from glycolysis (Figure 2.9A). The higher contribution of mitochondria to total 
cellular ATP in OxPhos-DLBCLs is concordant with increased expression of mitochondrial ATP 
synthase  (complex  V)  subunits  (Figures  2.2,  2-S1  and  Table  2.1),  and  an  elevated  rate  of 
mitochondrial ATP synthesis in OxPhos-DLBCL cell lines (Figure 2.9B). These observations 
could  potentially  be  explained  by  differences  in  mitochondrial  content  in  DLBCL  subtypes. 
However, assessment of the steady state content of mitochondria in DLBCL cell lines did not 
reveal  any  subtype-specific  differences  (Figure  2.10A).  In  addition,  mitochondrial  SNP  copy 
number analysis in a cohort of primary biopsies with OxPhos or BCR assignments did not reveal 
any differences (Figure 2.9C). Consistent with the significant mitochondrial contribution to total 
cellular energy budget in OxPhos-DLBCLs, the survival of this subtype was selectively sensitive 
to hypoxia, which limits mitochondrial function and diminishes oxidative phosphorylation (Figure 
2.11A). Conversely, viability in galactose containing media, which forces cells to use oxidative 
phosphorylation over glycolysis, was maintained in OxPhos-DLBCL cells but was significantly 
compromised in the more glycolytic BCR-DLBCL subset (Figure 2.11B). 
Increased contribution of mitochondria to total cellular ATP may not only reflect distinct 
channeling  of  carbon  substrates  in  mitochondria  but  also  differential  activity  or  efficiency  of 
mitochondrial ETC complexes. Studies in isolated mitochondria derived from DLBCL cell lines 
enabled direct assessment of mitochondrial respiration at the organelle level independent of the 
cytosolic processing of carbon substrates. Mitochondrial respiratory states were assessed using 
glutamate/malate and succinate as complex I- and II-linked substrates, respectively (Figures 
2.9D and 2.9E). When measuring complex II activity, rotenone was included with succinate to 
inhibit the reverse flow of electrons to complex I. Respiratory rates in the presence of substrate 


















Figure 2.11. Differential sensitivity of DLBCL cell lines to hypoxia and galactose 
(A) Viability of DLBCL cell lines after incubation for 72 hr in 1% O2. (B) Viability of DLBCL cell 
lines grown in serum-free RPMI containing 2 g/L D-glucose or 2 g/L D-galactose for 72 hr. 
Error bars, ± SEM. *p <0.05; ***p < 0.001; two-tailed Student’s t-test. 
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(Figure 2.9F). Addition of ADP which mimics a state of energy demand driving high rates of 
respiration  (also  known  as  state  III  respiration)  elicited  significantly  higher  OCR  in  OxPhos-
DLBCL  mitochondria  supplied  with  either  complex  I  or  II  substrates  (Figure  2.9F).  This 
increased  respiration  is  used  for  ATP  synthesis  and  is  sensitive  to  oligomycin.  Accordingly, 
OCR values in the presence of substrate, ADP and oligomycin (state IV respiration) were also 
significantly  higher  in  OxPhos-  compared  with  BCR-DLBCLs  (Figure  2.9F).  These  results 
provide a direct link between the OxPhos signature and an actual quantitative increase in ETC 
activity  in  this  DLBCL  subset.  Moreover,  independent  biochemical  measurements  of 
mitochondrial complex I, II and IV in immunocapture assays provided corroborative biochemical 
evidence for significant elevation of these enzyme activities in OxPhos-DLBCLs (Figure 2.10B). 
In aggregate, our observations both at the level of intact cells (Figures 2.4A, 2.9A, 2.9B and 
2.11)  and  isolated  mitochondria  (Figures  2.9F  and  2.10B)  demonstrate  that  the  OxPhos 
signature  captures  a  program  of  mitochondrial  metabolism  and  energy  transduction  that  is 
selectively activated in this DLBCL subset.     
 
The relevance of ROS content and glutathione synthesis in DLBCL subtypes 
Mitochondria are a predominant source of reactive oxygen species (ROS). While ROS 
signaling is important for a myriad of cellular functions, excessive mitochondrial superoxide can 
damage mtDNA, modify proteins and lipids, and inhibit aconitase activity, thus limiting oxidative 
phosphorylation. Elevated ETC activity in OxPhos-DLBCLs, particularly of complex I, predicted 
increased accumulation of mitochondrial superoxide. However, MnSOD is also concomitantly 
elevated in this subset (Figures 2.2, 2.3, and 2-S1), potentially as a mechanism to counteract 
the increased burden of mitochondrial superoxide. Efficient clearance of ROS would also ensure 
that  oxidative  phosphorylation  could  remain  elevated  in  OxPhos-DLBCLs.  Assessment  of 
mitochondrial superoxide using MitoSOX Red revealed lower steady state levels in OxPhos-










Figure  2.12.  Differential  contribution  of  ROS  detoxification  to  survival  of  DLBCL 
subsets 
(A)  Mitochondrial  superoxide  (left),  total  cellular  ROS  (middle)  and  GSH  (right)  levels  in 
DLBCL subtypes. Data are derived from four cell lines per DLBCL subset listed on top. (B-C) 
De novo GSH synthesis pathway (B) and the effect of GCS depletion on DLBCL survival. 
Cell viability was assessed 72 hr after knockdown. GCS, γ-glutamyl cysteine synthase. Error 




These  observations  were  further  integrated  with  the  total  cellular  ROS  levels  using  CM-
H2DCFDA, a fluorescent probe that is sensitive to oxidation by peroxyl, alkoxyl, peroxynitrite, 
NO2˙, CO3˙
−, and OH˙ radicals and can thus serve as an indicator of overall “oxidative stress”. 
The  CM-H2DCFDA  signal  intensity  was  also  significantly  lower  in  OxPhos-DLBCLs  (Figure 
2.12A, middle panel). A potential explanation for these observations is increased diversion of 
peroxide generated from the SOD-catalyzed reaction into the antioxidant glutathione system. 
Consistent with this possibility, glutathione (GSH) levels were significantly higher in OxPhos-
DLBCLs (Figure 2.12A, right panel), suggesting increased capacity for ROS detoxification.  
Given the quantitative differences in ROS and GSH content in DLBCL cell lines, we 
hypothesized that the capacity to maintain a large GSH pool may be required for the survival of 
OxPhos-DLBCLs.  To  test  this  possibility,  de  novo  GSH  synthesis  was  inhibited  by  shRNA-
mediated depletion of γ-glutamyl cysteine synthase (GCS), a rate limiting enzyme that catalyzes 
the introduction of an amide linkage between the γ-carboxyl group of glutamate and cysteine 
(Figure 2.12B). OxPhos-DLBCL cell lines were significantly more sensitive to GCS knockdown 
compared with the BCR subset (Figures 2.12C and 2-S7), suggesting that they may be more 
reliant on GSH for survival.  
 
DISCUSSION 
Our integrative analysis using proteomics, mitochondrial respirometry and metabolomics 
have unraveled metabolic distinctions in DLBCL subsets. We show that compared with “non-
OxPhos”/BCR-DLBCLs, nutrient and energy metabolism in OxPhos-DLBCLs has a significant 
mitochondrial component, marked by elevated oxidative phosphorylation, increased contribution 
of mitochondria to total cellular energy budget, greater incorporation of fatty acid- and glucose-
derived carbons into the TCA cycle, and increased lipogenesis from these carbon substrates. In 
comparison, the “non-OxPhos” DLBCLs have greater glycolytic flux. These studies also provide  
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a  clear  example  of  heterogeneity  in  fuel  utilization  pathways  even  within  the  same  disease 
entity.  
The differential utilization of glucose- and fatty acid-derived carbons in OxPhos versus 
“non-OxPhos”  DLBCLs  appears  to  parallel  the  absence  or  presence  of  functional  BCR 
signaling,  respectively.  This  is  consistent  with  our  observations  that  acute inhibition of BCR 
signaling  upon  SYK  and  CD79B  depletion  is  sufficient  to  enhance  palmitate-induced 
mitochondrial OCR in BCR-DLBCL cell lines. BCR-derived signals are critical for growth and 
survival of mature B-cells as well as multiple B-cell lymphomas [30]. These signals also trigger 
glucose utilization in a PI3K-dependent manner that is marked by an initial increase in lactate 
production and a subsequent shift to the pentose phosphate pathway during progression to S 
phase [31]. Reduction in glycolytic flux and incorporation of glucose carbons into the pentose 
pool in OxPhos compared with “non-OxPhos” DLBCLs is consistent with published observations 
that  OxPhos-DLBCLs  do  not  display  the  full  phospho-pattern  of  signaling  intermediates 
following BCR crosslinking and are insensitive to inhibitors of BCR signaling [18].  
The  common  metabolic  profile  of  “non-OxPhos”  DLBCLs  is  striking  given  that  these 
tumors  rely  on  multiple  components  of  BCR  signaling  [18,  32,  33].  This  may  suggest  that 
proliferation and survival mechanisms in these tumors may converge on glycolysis. The clear 
distinction  between  the  metabolic  profiles  of  OxPhos-  and  BCR-DLBCLs  suggests  that  the 
specific pattern of nutrient metabolism in the former may provide an alternative survival program 
independent of the BCR network. Moreover, the OxPhos metabolic signature may have broader 
implications  for  other  tumor  types  that  are  independent  or  have  lost  dependency  on  the 
components of BCR signaling. 
Several  independent  approaches  to  inhibiting  the  mitochondrial  FAO  program 
significantly compromised the survival of OxPhos-DLBCL. Within this context, BrCA-mediated 
inhibition of mitochondrial FAO and pharmacologic or genetic interference with PPARγ were 
selectively toxic to OxPhos-DLBCLs. The relevance of PPARγ in multiple cancer models and the  
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anti-tumor effects of its inhibition have been reported [34]. Increased PPARγ activity has been 
recently implicated in differentiation and stimulation of antibody production in normal human B-
lymphocytes  [35].  Whether  this  is  accompanied  by  increased  FAO  in  normal  lymphocytes 
remains to be determined. Nevertheless, it is possible that the metabolic signature of OxPhos-
DLBCL represents pathways relevant to B-lymphocytes that are further modified to fulfill the 
nutrient and energy requirements of these tumors.  
Findings in other cancer models have suggested that FAO may serve as an alternative 
survival  pathway  that  is  triggered  by  glucose  deprivation  or  lack  of  glucose  uptake  [1,  36]. 
Moreover,  a  recent  report  showed  increased  FAO  in  solid  tumors  contributes  to  rapamycin 
resistance [12]. The survival-promoting effect of fatty acid metabolism has also been reported in 
a  leukemia  model  [37].  In  this  model,  increased  fatty  acid  metabolism  was  decoupled  from 
oxidative phosphorylation, which appears to be distinct from enhanced ATP-coupled OCR in 
response to palmitate in OxPhos-DLBCLs. 
Concomitant utilization of palmitate-derived acetyl-CoA for ATP production and citrate 
synthesis  in  OxPhos-DLBCLs  suggests  FAO  and  fatty  acid  synthesis  may  be  concurrent 
pathways in these cells. This may be surprising in light of the inhibitory effect of citrate-derived 
malonyl-CoA  on  mitochondrial  transport  of  long-chain  fatty  acids  through  carnitine 
palmitoyltransferase  (CPT)1.  However,  several  possibilities  may  explain  these  observations. 
The potency of inhibition by malonyl-CoA differs between the two CPT1 isoforms and is likely 
further influenced by their relative abundance [38]. CPT1A is ~80 fold less sensitive to malonyl-
CoA than CPT1B and the ratio of CPT1A to 1B expression is higher in OxPhos-DLBCLs. The 
relative abundance of CPT1A and the possibility that malonyl-CoA may be used rapidly prior to 
its accumulation may explain how mitochondrial FAO could proceed unhindered in these cells. 
A  scenario  for  rapid  utilization  of  malonyl-CoA  is  active  fatty  acid  synthesis  as  would  be 
expected in a proliferating cell. In addition, fatty acid synthesis may serve as a “sink” for excess 
acetyl CoA/citrate generated due to enhanced FAO and increased entry of acetyl-CoA into the  
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TCA cycle. Concurrent FAO and fatty acid synthesis in other tumors has been observed [39, 
40].  It is also interesting to note that increased FAO in AML has been linked to a quiescent pool 
of tumor-initiating cells [37]. The precise molecular basis for concomitant use of fatty acids for 
ATP production and citrate synthesis in OxPhos-DLBCLs awaits future studies.  
Parallel activation of an antioxidant defense mechanism with increased mitochondrial 
FAO in OxPhos-DLBCLs is intriguing. A link between FAO and antioxidant capacity has been 
previously suggested. For example, mitochondrial FAO may serve as a source of NADPH to 
regenerate GSH [41]. On the other hand, a reduced cellular redox state may be important for 
completion of β-oxidation [36, 42]. It is also possible that elevated GSH in OxPhos-DLBCL is 
secondary to its increased synthesis from glutamate. This is consistent with higher enrichment 
of fatty acid-derived glutamate in this subtype. While increased GSH and MnSOD levels are in 
agreement with lower ROS content, additional mechanisms contributing to ROS handling in 
OxPhos-DLBCLs cannot be excluded.  
Our  findings  provide  functional  validation  of  quantifiable  metabolic  differences 
associated with transcriptionally defined subsets of DLBCL. These observations also indicate 
that  the  OxPhos  molecular  signature  is  a  bona  fide  metabolic  program  that  is  selectively 
activated  in  these  lymphomas,  providing  distinct  growth  and  survival  benefits.  Detailed 
fingerprints  of  the  DLBCL  metabolome  may  uncover  important  insights  into  the  molecular 
pathogenesis and underlying heterogeneity of these lymphomas as well as additional roadmaps 
to subtype-specific therapeutic targets.   
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MATERIALS AND METHODS 
Primary DLBCL biopsies 
Protein samples were prepared from frozen biopsy specimens of newly diagnosed, previously 
untreated  primary  DLBCLs  with  >  80%  tumor  involvement  according  to  Institutional  Review 
Board-approved protocols from two institutions (Brigham & Women’s Hospital and Dana-Farber 
Cancer  Institute).  A waiver  to  obtain  informed  consent  was  granted  by  the  IRBs  because 
otherwise discarded tissue was used. The frozen biopsy specimens from which total RNA and 
high molecular weight DNA were extracted for transcript abundance and SNP analysis have 
been described in a recent study [43]. 
 
Classification of DLBCL primary tumor biopsies based on RNA profiles 
Primary DLBCL samples were assigned to consensus clusters using their transcriptional profiles 
and an ensemble classification scheme previously described [22]. In particular, 13 independent 
classifiers were trained on the original 141-sample series of DLBCL samples [15] and applied to 
the 233 R-CHOP treated samples to be classified [21]. Class membership was determined by 
majority  voting,  and  samples  with  fewer  than  10  of  13  classifiers  in  agreement  were  left 
unassigned. The number and identity of the predictive features (probe sets) used to build each 
of the 13 classifiers were determined by leave-one-out cross-validation in the training set.  
 
Cell culture, inhibitor, hypoxia and galactose treatments and viability assays  
DLBCL cell lines used in this study (Karpas 422, OCI-Ly4, Pfeiffer, Toledo, SU-DHL-4, SU-DHL-
6, OCI-Ly1, OCI-Ly7, OCI-Ly3, OCI-Ly10, HBL-1 and U2932) have been previously described 
[18,  33].  The  consensus  cluster  (CC)  assignments  of  these  DLBCL  cell  lines  have  been 
previously defined [18, 22]. The cell-of-origin (COO) designation was determined based on the 
previously described linear predictive score (LPS) method [17], built upon the 23 (of 27) COO 
probe sets represented in the microarray. Cell lines were assigned to the GCB class if their  
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classification probability was greater than 0.9, to the ABC class if their probability was less than 
0.1, and to Type 3 otherwise. Intact BCR signaling and dependency on BCR-mediated survival 
signaling has been confirmed for the HBL-1 and U2932 “ABC-type” DLBCL cell lines [[44] and 
Margaret Shipp, personal communication]. 
All cell lines were grown in RPMI supplemented with 10% fetal bovine serum, 2 mM 
glutamine,  and  1%  penicillin/streptomycin  with  the  following  exceptions.  HBL-1  cells  were 
cultured in the above medium containing 1% sodium pyruvate. OCI-Ly3 and OCI-Ly10 cells 
were  cultured  in  IMDM  supplemented  with  20%  fetal  bovine  serum  or  human  serum  AB 
(Gemini, West Sacramento, CA), respectively. For inhibitor studies, 2.5x10
6 cells were treated 
with 4-bromocrotonic acid (International Lab, San Francisco, CA) at 7.5 µM for 24 hr or with 
T0070907  (Sigma)  or  GW9662  (Sigma)  at  indicated  concentrations  for  96  hr  at  37°C.  For 
assessment of cell viability under hypoxia, cells were grown in 1% O2 or atmospheric O2 for     
72 hr at 37°C in complete media. For assessment of viability in galactose containing media, 
cells  were  grown  in  serum-free  RPMI  (US-Biologicals)  supplemented  with  all  amino  acids 
except L-glutamine and either 2 g/L D-glucose (Sigma) or 2 g/L D-galactose (Sigma) for 72 hr at 
37°C.  Cell  viability  was  measured  using  the  Annexin  V/FITC  Apoptosis  Detection  Kit  (BD 
Bioscience) followed by flow cytometry.  
 
Mitochondria isolation  
Cells  were  resuspended  in  mitochondria  isolation  buffer  (MIB;  200  mM  mannitol,  70  mM 
sucrose; 1 mM EGTA; 10 mM HEPES, pH 7.4) containing protease inhibitors, homogenized 
with 20 strokes of a teflon-glass homogenizer, and resuspended in MIB. The nuclei and cell 
debris  were  removed  by  two  consecutive  centrifugations  at  1000  g  for  10  min  and  the 
supernatant containing crude mitochondria was centrifuged twice at 9000 g for 20 min. The 
resultant  pellet  contained  mitochondria-enriched  heavy  membrane  (HM)  fraction.  For  
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respirometry and enzyme activity assays, the HM fraction was resuspended in MIB. For 2D-
DIGE  analysis  (Figure  2-S1),  the  pellet  containing  the  HM  fraction  was  resuspended  in 
MOPS/mannitol buffer (5 mM MOPS, 300 mM mannitol, pH 7.5), carefully overlaid onto a 30/70 
% percoll/MOPS/mannitol gradient and centrifuged at 20,000 g for 40 min. Purified mitochondria 
were collected at the interface between the 30 and 70% percoll gradients, resuspended and 
washed three times in MOPS/mannitol buffer containing 1 mg/ml defatted BSA. 
 
Sample preparation and labeling for iTRAQ analysis  
Mitochondria  isolated  from  DLBCL  cell  lines  or  Trizol-purified  primary  biopsy  proteins  were 
solubilized  in  7.2  M  guanidine  hydrochloride,  100  mM  ammonium  bicarbonate.  Protein 
concentration  was  determined  by  the  Bradford  assay  (Bio-Rad,  Hercules,  CA)  and  equal 
amounts  of  protein  were  reduced  with  10  mM  DTT  for  30  min  at  56ºC,  and  alkylated  with      
22.5 mM iodoacetamide for 30 min at room temperature in the dark. DTT was added to a final 
concentration  of  20  mM  to  quench  the  remaining  iodoacetamide.  Proteins  were  digested 
overnight with trypsin (1:20) at 37ºC after addition of 100 mM ammonium bicarbonate solution to 
dilute the concentration of guanidine hydrochloride to 1 M. Digests were acidified with 10% TFA 
and desalted by C18.  Aliquots of peptides were stored at -80ºC.   
Mitochondria derived peptides (50 µg) from three OxPhos (Karpas 422, Toledo, and Pfeiffer) 
and three BCR (OCI-Ly1, SU-DHL-4, and SU-DHL-6) cell lines were solubilized in 100 µL of 
30% 500 mM triethylammonium bicarbonate, pH 8.5/70% ethanol and 1 unit of iTRAQ 8-plex 
reagent was added to each sample (Karpas 422-113, Toledo-114, Pfeiffer-115, OCI-Ly1-117, 
SU-DHL-4-118, SU-DHL-6-119; note 116 and 121 reagents were not used). The solution was 
incubated for 1 hr at room temperature, and the reactions were combined and dried by vacuum 
centrifugation. Labeled peptides were desalted by C18, dried again by vacuum centrifugation, 
and stored at -80ºC. The same procedure was used to label 100 µg aliquots of primary DLBCL  
! 59 
biopsy-derived  peptides  with  iTRAQ  4-plex  reagent  [biopsy  #32  (OxPhos)-114;  biopsy  #39 
(OxPhos)-115; biopsy #42 (BCR)-116)].  
 
LC-MS/MS analysis of iTRAQ-labeled samples  
Approximately  500  ng  of  iTRAQ  labeled  peptides  were  analyzed  in  duplicate  by  nano  LC-
MS/MS [45] using a NanoAcquity UPLC system (Waters, Milford, MA) and quadrupole time-of-
flight mass spectrometer (TripleTof 5600, ABSciex, Framingham, MA) equipped with a Digital 
PicoView  ESI  source  (New  Objective,  Woburn,  MA).  Peptides  were  resolved  on  a  25  µm 
analytical  column  packed  with  100  cm  5  µm  monitor  C18  and  introduced  to  the  mass 
spectrometer at a flow rate of ~10 nL/min using an HPLC gradient (4-55% B in 600 min; spray 
voltage=2800V) [46]. The mass spectrometer was operated in data dependent mode, with the 
top 50 precursors (charge state +2 to +5, >50 counts) in each MS scan (800 ms, scan range 
350-1500 m/z) subjected to MS/MS (minimum time 100 ms, scan range 100-1800 m/z). 
 
LC-MS/MS data processing for iTRAQ analysis  
Data files were converted to .mgf using MSDataConverter version 4.0.404 (ABSciex) with the 
protein pilot peak generation algorithm, and re-calibrated using parameters derived from fitting 
experimentally observed masses in high confidence peptide identifications. Files were searched 
using Mascot version 2.2.1 against a forward-reversed human (38190 forward entries) NCBI 
refseq  database  (downloaded  Nov.  2009)  with  an  appended  cRAP  [common  repository  of 
adventitious proteins [47]] database of 752 entries. Precursor and product ion tolerances were 
both 0.5 Da. Search parameters included trypsin specificity, up to 2 missed cleavages, fixed 
carbamidomethylation  (C),  variable  oxidation  (M)  and  fixed  iTRAQ  modification  (N-term,  K). 
After  searching,  an  excel  spreadsheet  containing  the  Mascot  search  results  was  generated 
using Multiplierz version 0.8.3 [48]. Data were first processed to remove reverse database hits 
and  forward  hits  with  FDR  >1.0%,  and  then  to  remove  identifications  with  mass  deviations  
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greater than 25 ppm. iTRAQ reporter ion intensities were corrected for isotopic impurities as 
well  as  minor  variations  in  source  protein  concentration.  Abundance  ratios were  derived  by 
summing reporters for all peptides mapping to unique genes across replicates, and only genes 
represented by 2 or more unique peptides are reported.  
 
Mitochondrial respirometry  
OCR was measured in real time using the XF24 extracellular flux analyzer instrument and the 
AKOS algorithm v1.5.069 software (Seahorse Bioscience Inc., North Billerica, MA). For whole 
cell studies, cells were seeded on XF24 V7 plates coated with Cell-Tak (BD Biosciences) at 
3x10
5 cells/well in 600 µl of sodium bicarbonate-free RPMI medium alone or supplemented with        
10 mM glucose, 2 mM glutamine or 0.2 mM palmitate. When palmitate was tested, 0.5 mM 
carnitine  was  included  in  the  incubation/equilibration  medium  to  ensure  import  of  BSA-
conjugated  palmitate  into  mitochondria.  The  plates  were  spun  at  500  rpm  (breaks  off)  and 
incubated at 37°C for 10 min to ensure cell attachment. Measurements were taken for a total of 
60 min, including a 12 min incubation period prior to starting baseline measurements. Within this 
assay time, OCR was measured for 3 min periods with 5 min intervals between measurements. 
After baseline measurements, 2.5 µM oligomycin was added in a single 75 µl injection. In all 
experiments, parallel samples were run in the absence of oligomycin to ensure stable baselines 
as a quality control parameter for the bioenergetic health of the cells.  
 
Determination of oxygen consumption rate (OCR) in isolated mitochondria  
OCR was measured in real time using the XF24 extracellular flux analyzer instrument and the 
AKOS algorithm v1.5.069 software (Seahorse Bioscience Inc., North Billerica, MA). Briefly, the 
heavy membrane fraction containing mitochondria was prepared as above and loaded on XF24 
V7  plates  at  15  µg/well  in  100  µL  of  mitochondria  assay  solution  (MAS;  70  mM  sucrose,         
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220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES pH 7.2, 1 mM EGTA, 0.2% 
defatted BSA). The plates were spun at 3400 rpm for 10 min at 4ºC. An additional 300 µl MAS 
was  added  and  the  plates  were  incubated  at  37°C  for  10  min  in  the  absence  of  CO2. 
Mitochondrial respiration was measured in different respiratory states as previously established 
[49]. Briefly, OCR measurements were taken in 4 or 6 min periods with 30 s intervals between 
measurements for a total assay time of 37 min. State II respiration (non-phosphorylating state) 
was  measured  upon  addition  of  glutamate/malate  or  succinate  as  respiratory  substrates  at        
5 mM each in 100 µl MAS. Glutamate/malate donate electrons to complex I via NADH, and 
succinate donates electrons to complex II via FADH2. Succinate was combined with 2.5 µM 
rotenone to inhibit the reverse flow of electrons to complex I. For measurement of state III and 
IV,  2  mM  ADP  and  4  µM  oligomycin  were  sequentially  delivered  using  the  instrument’s 
individual  injection  ports.  After  oligomycin  administration,  two  additional  inhibitors  were 
consecutively injected for routine quality control assessment in all experiments. These included 
4  µM  of  the  uncoupler  FCCP  to  examine  the  maximal  ETC  activity  rate  when  the  electron 
transport was uncoupled from ATP synthesis, and 4 µM of antimycin A (AA) to inhibit the flow of 
electrons  through  complex  III,  preventing  the  oxidation  of  both  NADH  and  succinate  by 
mitochondria. 
 
13C Isotopomer-based metabolomics analysis  
10x10
6  cells  were  incubated  for  8  hr  at  37°C  in  glutamine-free  un-buffered  RPMI  medium 
containing  10  mM  malate,  0.5  mM  carnitine,  10  mM  β-hydroxybutyrate,  10%  (v/v)  FBS 
supplemented with 10 mM glucose, 4 mM glutamine, and 0.2 mM BSA-conjugated palmitate. 
When tracing glucose or palmitate carbons, the media was supplemented with U-
13C-glucose or 
U-
13C-palmitate  isotopomers  (Cambridge  Isotope  Laboratories)  to  the  final  concentrations  
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indicated above. Cell pellets and 1 ml aliquots of media were frozen on dry ice and processed 
for LC-MS/MS and GC/MS. 
  Cell pellets were lysed in methanol:water (1:1 v/v) via 3 cycles of freeze-thawing. The 
resulting  extraction  mixture  was  vortexed  for  30  min  and  insoluble  debris  were  removed  by 
centrifugation. The supernatants were taken for LC-MS analysis. Intracellular and media 
13C-
labelled intermediates were quantified using LC-MS/MS with an API4000 triple quadrupole MS 
system (AB Sciex, Framingham, MA). Analytes of interest were individually tuned and the most 
sensitive MRM was selected for each analyte. Waters Acquity UPLC HSS T3 2.1x100 mm,    
1.8 µm was used for all LC-MS/MS analysis. For TCA cycle intermediates, 5 mM dibutylamine 
acetate was used as mobile phase A and acetonitrile was mobile phase B. A gradient of 6 min 
at 0.20 mL/min from 1% to 30% of mobile phase B was employed. Amino acids were prepared 
for analysis using the AccQ-fluor reagent kit (Waters Corp, Milford, MA). The derivatized amino 
acids were separated on the Waters Acquity UPLC HSS T3 2.1x100mm, 1.8 µm column with a 
13.5 min gradient from 2% to 30% acetonitrile with 0.1% formic acid. The mobile A phase was 
0.1% formic acid in water. For the measurement of media U
13C-glucose, a three fold excess of 
acetonitrile was added to the conditioned media. The per-O-trimethylsilyl-O-methyl derivative of 
U
13C-glucose  was  generated  using  methoxamine  (MOX)  reagent  and  BSTFA  in  1%  TMCS 
(Thermo Fisher Scientific, Pittsburgh PA). Derivatized U
13C-glucose was measured by capillary 
GC/MS using Finnigan trace ultra gas chromatograph interfaced to a Finnigan trace DSQ mass 
spectrometer (Austin, TX). GC was performed on a Restek Rtx-5Sil MS capillary column (15 m 
X 0.25 mm i.d., 0.25 µm film thickness; flow-rate 1.0 ml/min He carrier gas; column temperature 
70°C for 1 min, programmed to 300°C at 20°C per min, held for 2 min). Mass spectra were 
obtained in single-ion monitoring (SIM) mode (323.2 m/z).  At least three separate injections 
were measured per sample and the percent enrichment of 
13C-labeled metabolites in the total 
metabolite pool was calculated for each metabolite. To facilitate comparison across a panel of 
eight cell lines and independent experiments, mean values for 
13C enrichment were determined  
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for all OxPhos and BCR cell lines, and these means were normalized to the composite mean 
percent enrichment of the four BCR cell lines. 
 
Knockdown studies  
The following lentiviral vectors containing short hairpins against SYK [50], GCS and CD79B 
were  purchased  from  The  RNAi  Consortium  (TRC,  the  Broad  Institute);  SYK 
(TRCN0000196401  (#1),  TRCN0000003163  (#3),  and  TRCN0000003164  (#4)),  GCS 
(TRCN0000048484  (#2)  and  TRCN0000048486  (#4)),  CD79B  (TRCN0000057650  (#1)  and 
TRCN0000057652 (#3)). In all experiments, shGFP was used as control. Viral supernatants 
were produced according to the TRC standard protocols and used to spinfect 500,000 cells for  
2 hr at 460 g at room temperature. The effect of SYK  or CD79B  knockdown on palmitate-
induced basal OCR was assessed after 24 hr. The effect of GCS knockdown on cell viability 
were assessed after 72 hr. 
For siRNA-mediated depletion of PPARγ, the following siRNAs were used; J-003436-09 
(#1), J-003436-08 (#2), and J-003436-07 (#3) (ONTARGETplus, Dharmacon). 5x10
5 cells were 
plated  in  500  µl  medium/well  in  a  12-well  plate.  For  each  transfection,  siRNAs  (final 
concentration  50  nM)  were  mixed  with  18  µl  Interferin  transfection  reagent  (Polyplus-
transfection, Illkirch, France) in 50 µl OPTI-MEM (Life Technologies). The mixture was vortexed 
for 10 s and incubated at room temperature for 10 min. The mixture was then added dropwise to 
the cells and the plate was gently swirled. On the following day, 500 µl of cell culture medium 
was added. Cell viability and knockdown efficiency was assessed 72 hr after transfection. 
 
Palmitate treatment and proliferation assays  
Cells were grown in amino acid-free and serum-free RPMI medium supplemented with amino 
acids  except  L-glutamine  to  final  concentrations  as  in  RPMI  standard  culture  medium.  This  
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medium was subsequently supplemented with either 0.5 mM carnitine alone or in combination 
with 0.2 mM palmitate. Cell proliferation was analyzed using the ClickIT EdU Flow Cytometry 
Assay kit (Invitrogen) following manufacturer’s instruction.  
 
Lactate measurements 
Extracellular  lactate  was  measured  using  the  Synchron  Systems  lactate  reagent  kit  per 
manufacturer’s instructions (Beckman Coulter). To derive the portion of lactate produced by 
glycolysis, cells were seeded exactly as they were in the whole cell respirometry assays and 
treated with 2.5 µM oligomycin, 20 mM 2-deoxyglucose (2DG), or 10 mM oxamate [51] for 2 hr 
at 37°C prior to sample collection. Glycolytically derived lactate was defined as the difference 
between lactate produced in the presence and absence of glycolytic inhibitors. 
 
Enzyme complex activity assays  
Complex  I,  II  IV  and  PDH  activity  were  assessed  in  isolated  mitochondria  (100  µg  for 
Complexes I, IV and PDH, 10 µg for Complex II) from each DLBCL cell line in 5-6 independent 
experiments  using  microplate  assay  kits  (MitoSciences,  Eugene,  OR)  per  manufacturer’s 
instructions. 
 
Analysis  of  cellular  ATP  content,  mitochondrial  ATP  synthesis,  and  energy  budget 
calculations  
ATP  content  was  measured  using  the  CellTiter  Glo  Luminescent  Assay  per  manufacturer’s 
instructions (Promega, Fitchburg, WI). The rate of mitochondrial ATP synthesis was determined 
as previously described [52]. Briefly, 2.5x10
5 cells were resuspended in 1 ml of buffer containing 
150 mM KCl, 25 mM Tris-HCl, 2 mM EDTA, 0.1% BSA, 10 mM K3PO4, 0.1 mM MgCl2, 40 µg/ml 
digitonin,  0.15  mM  P1,P5-Di(adenosine)  pentaphosphate  (an  inhibitor  of  adenylate  kinase),       
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10 mM malate, 10 mM pyruvate, and 1 mM ADP, with or without 1 µM oligomycin. Cells were 
incubated at 37°C for 15 min. At 0, 5, 10, and 15 min, 50 µl aliquots of the reaction mixture were 
quenched in 450 µl of boiling buffer containing 100 mM Tris-HCl and 4 mM EDTA (pH 7.75) for 
2 min. The aliquots were then diluted 1/10 in the quenching buffer and the quantity of ATP 
determined using CellTiter Glo. The rate of mitochondrial ATP synthesis was calculated from 
the difference in ATP content in the presence and absence of oligomycin. Each sample was 
analyzed in triplicate, with two to three independent experiments for each cell line.  
For energy budget calculations, the contribution of mitochondria and glycolysis to total 
cellular ATP was measured as previously reported [29]. Briefly, oxidative ATP turnover was 
calculated assuming a P/O ratio of 2.36, where P is nmol of ATP produced per nmol of oxygen 
consumed (O), which was in turn derived from the oligomycin-sensitive portion of OCR. The 
contribution of glycolysis to energy budget was calculated assuming a 1:1 stoichiometric ratio 
between glycolytically derived lactate (as described above) and glycolytically derived ATP. OCR 
and  lactate  measurements  were  done  over  a  2  hr  period.  For  each  cell  line,  nmol  of  ATP 
derived from glycolysis or oxidative phosphorylation were then pooled and percent contributions 
to the total ATP production were calculated. 
 
Mitochondrial copy number analysis 
The mitochondrial copy number was assessed using the mitochondrial SNP probes within the  
Affymetrix HD-SNP array 6.0 data from an independent series of primary DLBCL samples [[43], 
GEO  accession  number  GSE34171].  The  pre-segmentation  data  processing  was  performed 
according to the SNP array 6.0 analytical pipeline described in [53]. Gene expression profiling of 
the same samples allowed assignment of consensus cluster subtypes [[43], GEO accession 
number GSE34171]. Subsequently, the average copy number of 110 mitochondrial SNP probes 
was computed and visualized using a box plot for the 33 “BCR” and 39 “OxPhos” samples. 
Differences were tested using a Man-Whitney U-test [54].   
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Measurement of mitochondrial content in DLBCL cell lines  
1x10
6 cells per cell line were washed once with warm HBSS (with Ca
2+ and Mg
2+). Cell pellets 
were resuspended in 1 ml of HBSS solution containing 200 nM MitoTracker Red (Invitrogen) 
and  40  µM  verapamil  (Sigma)  and  incubated  at  37°C  for  15  min.  After  labeling,  cells  were 
washed once with HBSS and resuspended in 1 ml of fresh HBSS. The mean fluorescence 
intensity at 581 nm was analyzed by flow cytometry for each cell line.  
 
Assessment of mitochondrial superoxide, total cellular ROS levels and GSH content  
Steady state and antimycin A-induced mitochondrial superoxide levels were assessed using 
MitoSOX Red (Molecular Probes) and the ratio of induced to steady state values determined. 
Throughout  these  measurements,  the  effect  of  mitochondrial  membrane  potential  (ΔΨm)  on 
mitochondrial accumulation of MitoSOX Red was taken into account. Briefly, for steady state 
mitochondrial ROS measurements, 1x10
6 cells were washed with HBSS buffer containing Mg
2+ 
and Ca
2+ and incubated for 15 min at 37°C in 1 ml of HBSS solution containing 5 µM MitoSOX
 
Red and 40 µM verapamil (Sigma) to ensure stable maintenance of MitoSOX Red content within 
cells. In parallel cell samples, ΔΨm was analyzed using 50 nM tetramethylrhodamine, ethyl ester 
(TMRE; Molecular Probes) in the presence of 40 µM verapamil in normal culture media at room 
temperature for 60 min. MitoSOX Red and TMRE intensities were then assessed using flow 
cytometry.  MitoSOX  Red  intensity  values  were  normalized  to  TMRE  intensity  values.  For 
assessment of ROS levels induced by antimycin A, similar measurements were performed in 
the presence of 1 µM antimycin A (Sigma). The ratio of induced/steady state was calculated in 
multiple independent experiments using four independent cell lines per DLBCL subtype ran in 
triplicate and the mean of pooled values per DLBCL subtype was determined.  
Total  cellular  ROS  levels  were  measured  using  5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein  diacetate,  acetyl  ester  (CM-H2DCFDA,  Molecular  Probes).  Briefly, 
1x10
6 cells were washed and incubated in PBS containing 2 µM CM-H2DCFDA and 40 µM  
! 67 
verapamil for 60 min at 37°C. Cells were then resuspended in normal media and incubated for 
an  additional  15  min  before  flow  cytometry  measurement.  Parallel  positive  control  samples 
included cells treated with 50 µM tert-butylhydroperoxide, a potent inducer of ROS.  
GSH  content  was  measured  using  a  glutathione  assay  kit  (Northwest  Life  Science 
Specialties, LLC) per manufacturer’s instruction and used to derive GSH concentration. 
 
Statistical analysis 
Unless otherwise indicated statistical analysis was performed using two-tailed student’s t-test, 
assuming unequal variance. All values are presented as mean ± SEM. Significance indicated by 
p-values as follows: *p < 0.05, **p < 0.01, ***p < 0.001. Transcript abundance was visualized 
with box plots (median, line; 25% and 75% quartile, box; whiskers, minimum to maximum).    
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Contributions: 
Illana  Stanley  isolated  mitochondria  for  quantitative  proteomic  analysis  and  worked  in 
collaboration with Scott Ficarro and Jarod Marto (DFCI) to identify the mitochondrial proteome 
signature  of  DLBCL  subsets.  She  also  worked  collaboratively  with  Pilar  Caro  in  the  Danial 
laboratory on mitochondrial respirometry studies in intact cells and isolated mitochondria, and 
performed enzyme activity assays. In collaboration with Amar Kishan and Erik Norberg in the 
Danial laboratory, Illana assessed lactate production, mitochondrial content, and ROS levels in 
DLBCL cell lines. Erik Norberg performed knockdown studies. Amar Kishan analyzed cellular 
ATP budget, measured mitochondrial ATP synthesis rate, designed the metabolomics studies 
and  worked  collaboratively  with  John  Gounarides  at  the  Novartis  Institute  of  Biomedical 
Research to analyze metabolites. Analyses of gene expression profiles and mitochondrial SNP 
probes in primary DLBCL cases were conducted in collaboration with Margaret Shipp, Bjoern 
Chapuy (DFCI) and Stefano Monti (Boston University). Illana Stanley, together with Pilar Caro, 
Amar  Kishan  and  Erik  Norberg,  contributed  to  the  writing  and  revision  of  the  manuscript 
describing these studies, which was published in Cancer Cell (22:547-60, 2012) and selected as 
both a featured article and journal cover.  
 
The content of this chapter first appeared in the following publication: 
Caro,  P.,  A.  U.  Kishan,  E.  Norberg,  I.  A.  Stanley,  B.  Chapuy,  S.  B.  Ficarro,  K.  Polak,  D. 
Tondera, J. Gounarides, H. Yin, F. Zhou, M. R. Green, L. Chen, S. Monti, J. A. Marto, M. A. 
Shipp  and  N.  N.  Danial  (2012).  "Metabolic  signatures  uncover  distinct  targets  in  molecular 
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Differential Contribution of the Mitochondrial Translation Pathway to the Survival of 













Diffuse  Large  B-cell  Lymphomas  (DLBCLs)  are  a  highly  heterogeneous  group  of 
disorders in which subsets of tumors share molecular features revealed by gene expression 
profiles  and  metabolic  fingerprints.  While  B-cell  receptor  (BCR)-dependent  DLBCLs  are 
glycolytic, OxPhos-DLBCLs rely on mitochondrial energy transduction and nutrient utilization 
pathways  that  provide  pro-survival  benefits  independent  of  BCR-signaling.  Integral  to  these 
metabolic  distinctions  is  elevated  mitochondrial  electron  transport  chain  (ETC)  activity  in 
OxPhos-DLBCLs compared to BCR-DLBCLs, which is linked to greater protein abundance of 
ETC components. Here, we show that, compared to BCR-DLBCLs, the mitochondrial proteome 
of  OxPhos-DLBCLs  is  enriched  in  mitochondrial  translation  factors,  and  the  mitochondrial 
translation pathway is required for increased ETC activity and mitochondrial energy reserves in 
this  subtype.  Importantly,  genetic  or  pharmacological  perturbation  of  the  mitochondrial 
translation pathway is selectively toxic to OxPhos-DLBCL cell lines and primary tumors. These 
findings  provide  additional  molecular  insights  into  the  metabolic  characteristics  of  OxPhos-
DLBCLs, and mark the mitochondrial translation pathway as a target in these tumors that may 













The mitochondrial electron transport chain (ETC) is comprised of a series of large multi-
subunit complexes housed within the mitochondrial inner membrane, which carry out multiple 
redox  reactions  that  ultimately  lead  to  reduction  of  molecular  oxygen  to  water.  The  initial 
electron donors for these reactions are supplied by the TCA cycle in the form of NADH and 
FADH2.  Respiratory  chain  complexes  I  (NADH  dehydrogenase),  III  (ubiquinol-cytochrome  c 
reductase), and IV (cytochrome c oxidase) extrude protons across the inner membrane while 
transferring electrons. The resulting proton gradient is subsequently coupled to ATP synthesis 
by  the  activity  of  the  F0F1  ATP  synthase  (complex  V),  completing  the  process  of  oxidative 
phosphorylation  (OXPHOS).  Except  for  complex  II  (succinate  dehydrogenase),  the  protein 
constituents  of  the  ETC  complexes  are  encoded  by  two  independently  transcribed  and 
translated genomes; nuclear and mitochondrial [1, 2]. The mitochondrial DNA (mtDNA), which 
encodes 13 subunits of complexes I, III, IV and V, 22 transfer RNAs, and 2 ribosomal RNAs 
(Figure 3.1), is a remnant of the mitochondrion’s evolutionary origin as a symbiotic prokaryotic 
partner to early eukaryotes. The mechanism for decoding the mitochondrial genome requires a 
host  of  nuclear  encoded  factors,  including  ribosomes,  translation  initiation  and  elongation 
factors, and tRNA synthetases that are distinct from the cytoplasmic counterparts dedicated to 
translation  of  nuclear  transcripts  [3,  4].  Mutations  in  mtDNA  and  mitochondrial  translation 
factors are associated with ETC failure in several human pathologies [5-11], highlighting the 
functional  relevance  of  the  mitochondrial  genome.  In  addition  to  coordinate  synthesis  of 
respiratory chain subunits encoded by the nuclear and mitochondrial genomes, the functional 
fidelity of the ETC is influenced by proper assembly and organization of ETC complexes in the 
inner membrane. ETC complex assembly is modulated by dedicated chaperones and assembly 





Figure 3.1. Schematic of the mitochondrial translation machinery 
Illustration  of  the  three  phases  of  mitochondrial  translation;  initiation,  elongation  and 
termination, as well as the required tRNA processing step to generate aminoacyl-tRNAs for 
the translation of mtDNA-encoded genes. Key nuclear encoded proteins involved in these 
processes,  which  are  imported  into  the  mitochondria  through  the  TOM  and  TIM  protein 
translocation  machinery,  are  also  listed.  mtDNA  in  the  mitochondrial  matrix  encodes  22 
tRNAs, 2 rRNAs and 13 peptides. Translation of the 13 protein coding genes takes place in 
the mitochondrial matrix by a dedicated system of mitochondrial ribosomes (large 39S and 
small 28S subunits) and mitochondrial initiation, elongation and termination factors. During 
initiation, the mitochondrial mRNA docks with the small 28S mitochondrial ribosomal subunit 
at  the  start  codon.  During  elongation,  the  large  39S  subunit  docks  with  the  29S/mRNA 
complex, and aminoacyl-tRNAs are successively recruited based on base pairing with the 
mRNA codon. At termination, the small and large subunits dissociate with the assistance of 
the dedicated termination factors. The released polypeptides, together with nuclear encoded 
subunits,  contribute  to  the  synthesis  of  complexes  I,  III,  IV  and  V  (ATP  synthase). 
Highlighted  in  green  are  proteins  that  were  enriched  in  the  OxPhos-DLBCL  proteomic 
analysis shown in Figure 3.2 and Table 3-S2). Graphics are courtesy of Benjamin Szlyk and 
Eric Smith.  
Abbreviations: mtDNA - mitochondrial DNA, tRNA - transfer RNA, rRNA - ribosomal RNA, 
mRNA - messenger RNA, TOM - translocase of the outer mitochondrial membrane, TIM - 
translocase of the inner mitochondrial membrane, I, II, III, IV & V - ETC complexes I, II, III, IV 
and V. ! 
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The  balance  between  OXPHOS  and  glycolysis,  the  extent  of  ETC  activity,  and  the 
contribution of mitochondria-derived ATP to total energy budget vary widely among tumors [15]. 
In terms of bioenergetics, some tumors are oxidative, others are glycolytic, and some display 
both features [15-19]. As described in Chapter 2, the metabolic heterogeneity in the molecular 
subtypes of Diffuse Large B-cell Lymphoma (DLBCL) includes clear distinctions at the level of 
mitochondrial function [19]. Specifically, BCR-DLBCLs have greater glycolytic flux typical of the 
Warburg phenotype [19]. Unlike BCR/Warburg-type DLBCLs, OxPhos-DLBCLs display elevated 
ETC  activity  and  mitochondrial  ATP  production,  channel  the  majority  of  glucose-derived 
pyruvate  into  the  TCA  cycle  via  increased  pyruvate  dehydrogenase  activity,  and  exhibit 
increased mitochondrial oxidation of fatty acids [19]. Importantly, these distinct metabolic and 
bioenergetic  profiles  are  associated  with  survival  mechanisms  and  predictable  metabolic 
vulnerabilities. For example, the glycolytic phenotype of BCR-DLBCLs renders them resistant to 
hypoxia, which blunts OXPHOS, but sensitive to growth in galactose, which shifts metabolism 
from glycolysis to OXPHOS (Figure 2.11). In comparison, the predominance of mitochondrial 
metabolism  in  OxPhos-DLBCLs  is  consistent  with  their  select  sensitivity  to  hypoxia  and 
resistance to apoptosis in galactose media (Figure 2.11). The differences in ETC activity and 
OXPHOS dependency among DLBCL subtypes warranted examination of pathways in charge 
of  synthesis  and  assembly  of  respiratory  chain  complexes.    Here,  we  interrogated  the 
mitochondrial translation machinery and its functional contribution to energy metabolism and 









Protein-level signatures capture enrichment of the mitochondrial translation pathway in 
OxPhos DLBCLs  
Our initial quantitative assessment of  the  mitochondrial  proteome  from  OxPhos-  and 
non-OxPhos/BCR-DLBCLs  revealed  enrichment  of  several  subunits  of  the  ETC  and  ETC 
assembly factors in OxPhos-DLBCLs that is consistent with increased respiratory activity in this 
subtype (Figure 2.2 and Table 2.1) [19]. However, these analyses, which were performed on an 
LC-MS/MS platform coupled to a single HPLC column for peptide fractionation (1D LC-MS/MS) 
[20],  captured  predominantly  protein-level  enrichment  of  nuclear  encoded  ETC  subunits. 
Because the resulting protein signature was associated with increased activity of several ETC 
complexes that are encoded by both the nuclear and mitochondrial genomes, we expected that 
the  enrichment  of  ETC  subunits  in  the  OxPhos-DLBCL  protein  signature  should  extend  to 
mtDNA-encoded  subunits  as  well.  For  this  reason,  we  turned  to  an  improved  proteomics 
platform,  with  higher  dynamic  range  and  increased  sensitivity  (3D  LC-MS/MS)  [21],  in 
conjunction  with  iTRAQ  labeling,  to  reassess  mitochondria  isolated  from  three  independent 
OxPhos-  and  three  independent  BCR-DLBCL  cell  lines.  These  analyses  not  only  captured 
enrichment  of  mtDNA-encoded  ETC  subunits  in  OxPhos-DLBCLs  compared  to  BCR 
counterparts  (Table 3-S1), but also revealed significantly higher levels of numerous nuclear 
encoded proteins involved in the translation of mitochondrial-encoded transcripts (Figure 3.2A-
D, Table 3-S2). Enriched proteins spanned several classes of mitochondrial translation proteins, 
including mitochondrial elongation factors (TuFM and GFM1), mitochondrial ribosomal proteins 
(MRP S5, S7, S9, S16, S22, S25, L12, and L46), and mitochondrial tRNA synthetases (DARS2 








Figure  3.2.  Enrichment of mitochondrial translation components  in  OxPhos-DLBCL 
mitochondria 
Multiplex iTRAQ analysis of isolated mitochondria from three independent OxPhos- (Karpas 
422, Pfeiffer, and Toledo) and three non-OxPhos/BCR- (OCI-Ly1, SU-DHL-4, and SU-DHL-
6)  DLBCL  cell  lines  using  the  3D  RP-SAX-RP  platform  (3D  LC-MS/MS).  (A)  Heat  map 
illustrating increased levels of mitochondrial translation proteins in OxPhos-DLBCL cell lines 
compared to BCR counterparts. OxPhos/BCR ratios on the right indicate abundance ratios 
derived by summing iTRAQ reporter ion intensities for all peptides mapping to unique genes 
across replicates per subtype. See also Table 3-S2. (B-D) MS/MS spectra of the indicated 
unique peptides for MRPS7 (B), GFM1 (C) and TuFM (D) recorded during 3D RP-SAX-RP 
analysis of mitochondrial proteins shown as an example of differentially enriched peptides. 
Ions of type b and y are shown in green and orange, respectively. Relative protein ratios in 
BCR- and OxPhos-DLBCL cell lines are derived from iTRAQ reporter ion intensities shown in 
inset mass spectrum. 
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Genetic  and  pharmacologic  inhibition  of  the  mitochondrial  translation  pathway  is 
selectively toxic to OxPhos-DLBCLs 
The robust quantitative enrichment of the mitochondrial translation pathway in OxPhos-
DLBCLs  warranted  examination  of  its  contribution  to  DLBCL  survival.  To  this  end,  several 
independent shRNA hairpins were used to deplete the two elongation factors, GFM1 and TuFM, 
and the mitochondrial ribosomal protein S7 (MRPS7) in four OxPhos- (Toledo, Pfeiffer, OCI-Ly4 
and Karpas 422) and four BCR- (SU-DHL-4, SU-DHL-6, U2932 and HBL-1) DLBCL cell lines, 
and  cell  viability  was  measured.  Knockdown  of  each  of  these  translation  factors  proved 
selectively toxic to OxPhos-DLBCL cell lines while sparing the non-OxPhos subset (Figures 
3.3A-C  and  3-S1A-C).  As  a  common  outcome  of  ETC  inhibition  is  the  generation  of 
superoxides,  the  toxic  effects  of  these  knockdowns  may  be,  in  part,  ROS  dependent.  This 
appears to be the case as pre-treatment with the anti-oxidant N-acetyl-cysteine (NAC) prior to 
knockdown partially, but significantly rescued cell death in this setting (Figure 3.3A-C).  
To  provide  a  pharmacologic  correlate  to  these  findings,  we  also  tested  the  effect  of 
tigecycline, a member of the glycylcycline class of antibiotics known to inhibit the prokaryotic 
ribosome [22, 23], which can also interfere with mitochondrial translation in eukaryotes [24]. 
Exposure to 1 µM tigecycline for 24 hr was sufficient to lower both cell growth and viability of 
OxPhos-DLBCLs without affecting BCR-DLBCLs (Figure 3.4A,B). As mitochondrial translation 
is an essential cellular process and BCR-DLBCLs have functional mitochondria (Figures 2.4A,B 
and 2.9A), we predicted that tigecycline toxicity in BCR-DLBCLs may manifest at higher doses. 
Assessment of dose-dependent toxicity of tigecycline over 0.125 to 30 µM concentration range 
indicated  that  a  significantly  higher  dose  (≥20  µM)  of  tigecycline  was  needed  to  kill  BCR-
DLBCLs, and that the toxicity dose curve of tigecycline in OxPhos-DLBCLs was shifted to the 
left (Figure 3.4B). Overall, our genetic and pharmacologic studies demonstrate that OxPhos-
























Figure 3.3. Differential requirement of the mitochondrial translation pathway for the 
survival of DLBCL subsets  
Effect of shRNA-mediated depletion of the mitochondrial translation elongation factors GFM1 
(A) and TuFM (B), and mitochondrial ribosomal protein MRPS7 (C) in four OxPhos- (Toledo, 
Pfeiffer, OCI-Ly4 and Karpas 422) and four BCR- (SU-DHL-4, SU-DHL-6, HBL-1 and U2932) 
DLBCL cell lines. Blue bars show rescue of cell  viability upon pre-treatment of cells with      
0.5  mM  N-acetyl-cysteine  (NAC)  prior  to  shRNA-mediated  knockdown.  Cell  viability  was 
assessed 24 hr after knockdown of the indicated mitochondrial translation factors. Error bars, 
± SEM, n=3-4 independent experiments per condition. *p < 0.05; **p < 0.01; ***p < 0.001; 












Figure 3.4. Cytostatic and cytotoxic effects of tigecycline in OxPhos-DLBCLs  
(A) The effect of 1 µM tigecycline on cell growth over 24 hr period in four OxPhos- (Toledo, 
Pfeiffer, OCI-Ly4 and Karpas 422) and four BCR- (SU-DHL-4, SU-DHL-6, U2932 and HBL-1) 
DLBCL cell lines. (B) Survival of DLBCL cell lines, as assessed by Annexin V/PI exclusion, 
following  24  hr  treatment  with  the  indicated  doses  of  tigecycline.  n=2-3  independent 
experiments per tigecycline concentration per cell line.! 
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Tigecycline  treatment  leads  to  reduced  electron  transport  activity  in  ETC  complexes 
containing mitochondrial-encoded subunits 
Inhibition of mitochondrial translation is expected to selectively affect the synthesis of 
peptides  encoded  by  the  mitochondrial  genome.  The  vast  majority  of  these  peptides  are 
components of the various ETC complexes with the exception of complex II, which is composed 
solely of nuclear-encoded proteins. To verify that tigecycline treatment selectively affects ETC 
complexes  containing  mitochondrial  encoded  subunits,  the  biochemical  activity  of  individual 
ETC complexes was measured in mitochondria isolated from cells treated with 1 µM tigecycline 
for 20 hr, a time point preceding the appearance of cytostatic and cytotoxic effects of tigecycline 
in  OxPhos-DLBCL  cells  (Figure  3.4A  and  data  not  shown).  In  particular,  mitochondrial 
respiration on glutamate/malate was used to assay complex I activity, the ETC complex with the 
largest contribution of subunits from the mitochondrial genome. Meanwhile, succinate was used 
as the substrate for measuring the activity of complex II (Figure 3.5A). Tigecycline had a larger 
effect on complex I respiratory rates in OxPhos-DLBCL cells as apparent from diminished rates 
in  response  to  ADP  (state  III  respiration)  and  the  uncoupler  FCCP,  which  drives  maximal 
respiration (Figures 3.5A,B and 3-S2). In comparison, complex II activity was minimally affected 
(Figures  3.5A,B  and  3-S2).  While  complex  II  abundance  is  not  expected  to  be  affected  by 
tigecycline treatment, the slight reduction in respiratory rates in response to succinate can be 
explained by the fact that complex III and IV, which are subsequent acceptors of electrons from 
complex II, have mtDNA-encoded subunits that are affected by tigecycline treatment (Figure 
3.5A).  
In whole cells, selective effects of tigecycline on mitochondrial bioenergetics in OxPhos-
DLBCLs were also evident from a significant decline in mitochondrial spare respiratory capacity 
(SRC)  (Figure  3.5C,D).  SRC  is  the  difference  between  mitochondrial  basal  and  maximal 
respiration (Figure 3.5C) and refers to the mitochondrial reserve capacity to produce energy 
under cellular stress and increased bioenergetic demand. SRC can significantly affect long-term  
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cellular  function  and  survival  [25,  26].  Compared  to  BCR-DLBCLs,  OxPhos-DLBCLs  have 
significantly  larger  SRC  under  steady  state  conditions  (control  in  Figure  3.5D),  which  is 
consistent with higher ETC activity and mitochondrial contribution to total cellular ATP [19]. The 
significant effect of 1 µM tigecycline on SRC in these cells is consistent with their heightened 
sensitivity to its toxic effects (Figures 3.4B and 3.5D).  
 
Increased  mitochondrial  superoxide  contributes  to  tigecycline-mediated  death  in 
OxPhos-DLBCLs  
Mitochondria are the major intracellular source of reactive oxygen species (ROS), and 
during normal physiological respiration about 1-2% of the molecular oxygen is converted into 
superoxide radicals, the precursor for most ROS. Defects in the shuttling of electrons through 
the  ETC  complexes  lead  to  electron  slippage  and  ROS  production  [27].  Consistent  with  its 
inhibition  of  ETC  activity,  tigecycline  treatment  was  associated  with  increased  mitochondrial 
superoxide in OxPhos-DLBCLs (Figure 3.6A). NAC treatment blunted the rise in mitochondrial 
superoxide and significantly rescued tigecycline-induced cell death in OxPhos-DLBCLs (Figure 
3.6A,B). These observations are consistent with NAC-mediated rescue of death induced by 
molecular  depletion  of  mitochondrial  translation  factors  (Figure  3.3A-C),  and  suggest  that 
tigecycline toxicity in OxPhos-DLBCLs is due, at least in part, to the elevated mitochondrial 










Figure 3.5. Effects of tigecycline on mitochondrial respiration  
(A-B) Complex I- and Complex II-linked oxygen consumption rates (OCR) in mitochondria 
isolated from OxPhos- (Pfeiffer, OCI-Ly4, and Karpas 422) and BCR- (SU-DHL-6) DLBCL 
treated with tigecycline. (A) Representative OCR traces of mitochondria isolated from one 
OxPhos-DLBCL  cell  line  (Pfeiffer)  supplied  with  complex  I-linked  (glutamate/malate)  or 
complex II-linked (succinate) substrates. (B) Cumulative data of ADP-stimulated (State III) 
respiration  derived  from  n=2-4  independent  traces  as  shown  in  (A).  (C-D)  The  effect  of 
tigecycline on mitochondrial spare respiratory capacity (SRC). (C) Representative trace of 
whole cell OCR indicating derivation of SRC. (D) SRC in DLBCL cell lines treated with 1 µM 
tigecycline for 15 hr, n=3-4 independent OCR measurements per condition in each cell line. 






Figure 3.6. Inhibition of the mitochondrial translation pathway stimulates ROS-
dependent cell death  
(A) Mitochondrial superoxide levels in DLBCL cells that were untreated or treated with 1 mM 
NAC and subsequently exposed to 1 µM tigecycline for 18 hr. (B) Survival of the indicated 
DLBCL  cell  lines  analyzed  24  hr  following  treatment with  tigecycline  and NAC  as  in  (A).   
















Figure 3.7. Differential sensitivity of primary OxPhos- and BCR-DLBCL tumor cells to 
tigecycline  
DLBCL  tumor  cells  were  isolated  from  two  OxPhos-  and  one  non-OxPhos/BCR-DLBCL 
cryopreserved patient samples and treated with the indicated concentrations of tigecycline. 
Cell survival was measured by Annexin V/PI exclusion 20 hr post treatment.  
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Differential toxicity of tigecycline in DLBCL subtypes extends to primary OxPhos- and 
BCR-DLBCL tumor cells  
We next wished to determine whether the differential contribution of the mitochondrial 
translation  pathway  to  the  survival  of  DLBCL  subtypes  could  be  substantiated  in  primary 
DLBCLs. To this end, tumor cells were purified from cryopreserved primary biopsies that were 
previously  classified  as  OxPhos-  or  BCR-DLBCL  using  consensus  clustering  classification 
(CCC) [28]. Primary DLBCL cells from two OxPhos- and one BCR-DLBCL biopsy were treated 
for 20 hr with 0.25 to 1 µM tigecycline followed by cell viability measurements. In concordance 
with  our  findings  in  DLBCL  cell  lines,  primary  OxPhos-DLBCL  cells  were  significantly  more 
sensitive to tigecycline treatment than non-OxPhos biopsies (Figure 3.7).  
 
DISCUSSION 
The current study provides biochemical and functional evidence for the mitochondrial 
translation  pathway  as  a  survival  mechanism  that  supports  a  central  metabolic  feature  of 
OxPhos-DLBCLs;  increased  mitochondrial  energy  transduction.  We  show  that  genetic  or 
pharmacologic  perturbations  of  the  mitochondrial  translation  apparatus  lead  to  subtype-
selective toxicity in OxPhos-DLBCL cell lines, which can also be corroborated in primary tumor 
cells  purified  from  newly  diagnosed,  previously  untreated  patient  biopsies.  At  the  molecular 
level, inhibition of the mitochondrial translation pathway is associated with reduced abundance 
of mtDNA-encoded ETC subunits that would disrupt the stoichiometric balance of mitochondrial- 
and nuclear-encoded components normally required for functional assembly and integrity of 
ETC complexes [29]. Interference with the mitochondrial translation apparatus has a greater 
bioenergetic  impact  on  OxPhos-  than  BCR-DLBCLs.  Compared  to  BCR-DLBCLs,  OxPhos-
DLBCLs have a significantly higher steady state mitochondrial spare respiratory capacity (SRC) 
that is consistent with increased ETC activity and mitochondrial ATP production in this subtype. 
Inhibition of the mitochondrial translation pathway in OxPhos-DLBCLs lowers the mitochondrial  
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SRC and increases mitochondrial superoxide production. Increased mitochondrial ROS is likely 
due to a greater probability of electron slippage when the functional integrity of ETC complexes 
is  diminished  [30],  and  has  been  previously  reported  in  the  context  of  perturbations  in 
mitochondrial translation factors [31, 32]. In addition, increased mitochondrial superoxide levels 
in  the  face  of  decreased  SRC  is  in  line  with  published  studies  that  have  implicated  the 
mitochondrial SRC as an important determinant of cells’ capacity to counter oxidative stress 
[33]. In light of these considerations, it is possible that diminished ETC function and SRC are 
part of a vicious cycle of oxidative stress that contributes to the toxicity associated with inhibition 
of mitochondrial translation in OxPhos-DLBCLs. The rescue of viability when cells are treated 
with an antioxidant prior to tigecycline exposure supports this scenario. 
The  dependency  of  OxPhos-DLBCLs  on  the  mitochondrial  translation  pathway  co-
segregates with increased abundance of mitochondrial translation factors, higher ETC activity, 
and greater reliance on oxidative phosphorylation in this subtype compared to BCR/Warburg-
type DLBCLs. Within this context, our findings are consistent with an earlier report that identified 
tigecycline  as  an  antileukemia  compound,  which  exerts  its  toxic  effect  through  inhibition  of 
mitochondrial  translation  [24].  Importantly,  increased  sensitivity  of  acute  myeloid  leukemia 
(AML) cell lines to tigecycline, compared to normal hematopoietic cells, was attributed to higher 
mitochondrial biogenesis and electron transport in AML cells. Of note, tigecycline treatment of 
AML cells was not associated with an increase in total cellular ROS, although mitochondrial 
superoxide  was  not  specifically  measured  [24].  However,  consistent  with  our  observations, 
studies  in  other  cell  types  reported  increased  mitochondrial  superoxide  content  following  
knockdown of mitochondrial translation factors and examination of MitoSOX Red and DHR123 
probe  intensities,  which  specifically  measure  mitochondrial  ROS  [31,  32].  The  basis  of  the 
difference between tigecycline’s effect on ROS content in DLBCL and AML cells is unclear. It is 
possible that, beyond inhibition of mitochondrial translation, tigecycline may invoke cell context- 
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specific mechanisms that contribute to its toxicity. In the context of OxPhos-DLBCLs, rescue 
studies using NAC support the idea that oxidative stress is a component of tigecycline toxicity.  
Our  results  extend  the  mitochondrial  proteomic  signature  of  OxPhos-DLBCLs  to 
numerous  mitochondrial  translation  factors  consistent  with  the  functional  significance  of  this 
pathway in OxPhos-DLBCLs. These observations raise the question as to the nature of this 
programmatic increase in the expression of the mitochondrial translation pathway. It is possible 
that  the  programmatic  enrichment  of  mitochondrial  translation  factors  is  transcriptionally 
regulated. Interestingly, several transcription factors that regulate OXPHOS genes also activate 
the expression of mitochondrial translation factors (cMYC, ERR, and YY1) [34, 35]. In addition, 
evidence  in  human  breast  cancer  biopsies  indicates  a  similar  increase  in  expression  of 
mitochondrial ribosomal subunits and other translation factors that appears to be associated 
with expression of NRF1, NRF2 and PGC1-α, which are transcription factors known to stimulate 
mitochondrial  biogenesis  [36].  The  molecular  basis  for  the  observed  enrichment  of 
mitochondrial translation factors in OxPhos-DLBCLs awaits future studies.  
Although downstream inhibitors of B-cell receptor signaling, including small molecule 
inhibitors of SYK and BTK kinases, are being evaluated in DLBCL [37, 38], there are currently 
no  clinically  approved  targeted  therapeutic  strategies  for  OxPhos-type  DLBCLs.  Our 
investigation of metabolic distinctions among DLBCL subtypes has led to the identification of 
several mitochondrial pathways, including fatty acid oxidation [19] and mitochondrial translation 
that provide selective pro-survival benefits to OxPhos-DLBCLs that, in the fullness of time, may 
prove clinically relevant. As such, tigecycline is an FDA-approved antibiotic that is being actively 
developed for its potential therapeutic benefits in AML and other hematologic malignancies as 
well as infectious diseases [39-41]. Our findings warrant investigation of the therapeutic utility of 




MATERIALS AND METHODS 
Cell culture, growth and viability assays 
All DLBCL cell lines were grown as previously described [19]. Cell growth was measured using 
CellTiter-Glo Luminescent Assay per manufacturer’s instruction (Promega). Cell viability was 
measured  using  Annexin  V/FITC  Apoptosis  Detection  Kit  (BD  Bioscience)  followed  by  flow 
cytometry.    
 
RNA interference 
Lentiviral  vectors  containing  short  hairpins  targeting  TuFM  (TRCN0000160152  and 
TRCN0000165471),  GFM1  (TRCN0000141319  and  TRCN0000144593),  and  MRPS7 
(TRCN0000117458 and TRCN0000117459) were purchased from The RNAi Consortium (TRC, 
the Broad Institute). An empty pLKO.1 vector was used for control. Viral supernatants were 
produced according to the TRC standard protocols and used to spinfect 500,000 cells for 2 hr at 
460  g  as  previously  described  [19].  The  effect  of  knockdown  on  cell  viability  and  protein 
depletion was assessed 24 hr after viral infection.  
 
Immunoblotting 
20  µg  of  whole  cell  lysates  were  fractionated  on  4-12%  gradient  NuPAGE  gels  and 
subsequently developed by western blotting using anti-GFM1 (Sigma, HPA 034765), anti-TuFM 
(Abcam,  ab85438),  anti-MRPS7  (Abcam,  ab140149),  and  anti-β-Tubulin  (Millipore,  05-661) 
antibodies.  
 
N-Acetyl Cysteine treatment 
N-acetyl cysteine (Sigma) was used as follows. In knockdown studies (Figure 3.3A-C), 0.5 mM 
NAC was added directly to the media following spinfection of DLBCL cell lines with lentiviruses 
bearing shRNA against GFM1, TuFM and MRPS7. For rescue of tigecycline toxicity, 1 mM NAC  
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was added 30 min prior to treatment with 1 µM Tigecycline. In each case, cell viability was 
assessed 24 hr after knockdown or tigecycline treatment using Annexin V/FITC as described 
above.  
 
Determination of mitochondrial superoxide content 
Mitochondrial superoxide was measured using MitoSOX Red (Molecular probes) as previously 
described [19]. All values were normalized to mitochondrial membrane potential as measured 
by TMRE (Molecular Probes).  
 
Analysis of primary DLBCL samples 
Cryopreserved viable primary DLBCL samples were obtained according to Institutional Review 
Board  (IRB)-approved  protocols  from  Mayo  Clinic,  Brigham  and  Women’s  Hospital  and  the 
Dana-Farber Cancer Institute. These anonymous primary tumor specimens were considered 
discarded  tissues  that  did  not  require  informed  consent.  For  assessment  of  tigecycline 
sensitivity, cryopreserved viable primary DLBCL samples were Ficoll purified, and tumor cells 
were treated with the indicated concentrations of tigecycline for 20 hr followed by measurement 
of cell viability using Annexin V/FITC Apoptosis Detection kit as described above.  
 
iTRAQ analysis of DLBCL mitochondria 
Sample  preparation  for  LC/MS.  Purified  mitochondria  were  solubilized  in  7.2  M  guanidine 
hydrochloride with 100 mM ammonium bicarbonate and protein concentrations determined by 
Bradford  assay  (Bio-Rad,  Hercules,  CA).  Equal  amounts  of  protein  were  reduced  with  DTT    
(10 mM final concentration) for 30 min at 56 ºC, and alkylated with iodoacetamide (22.5 mM) for 
30 min at room temperature in the dark. After adding additional DTT (final concentration 20 mM) 
and diluting guanidine hydrochloride concentration to 1 M with 100 mM ammonium bicarbonate, 
proteins were digested with trypsin overnight at 37 ºC. Digests were acidified with 10% TFA and  
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desalted by C18. Peptides (50 µg) from three OxPhos (Karpas 422, Toledo, Pfeiffer) and three 
BCR (OCI-Ly1, SU-DHL-4, SU-DHL-6) cell lines were solubilized in 100 µL of 30% 500 mM 
triethylammonium bicarbonate, pH 8.5/70% ethanol and 1 unit of iTRAQ 8-plex reagent was 
added to each sample (K422-113, Tol-114, Pf-115, Ly1-117, D4-118, D6-119).  Reactions were 
incubated for 1 hr at room temperature, combined, dried by vacuum centrifugation, desalted by 
C18, and dried again.     
3D  RP-SAX-RP  LC-MS/MS.  iTRAQ  labeled  peptides  (50  µg)  were  subjected  to 
multidimensional fractionation with a modified NanoAcquity UPLC system (Waters, Milford, MA) 
consisting of 2 binary pumps, an autosampler, and an additional 6-port, 2-position valve (Valco, 
Austin, TX) [21]. First dimension separations were conducted at high pH (10.0) using a reversed 
phase column (200 µm ID fused silica x 20 cm packed with 5 µM XBridge C18).  In the second 
dimension,  peptides  were  fractionated  by  strong  anion  exchange  chromatography  (200  µm 
fused silica x 20 cm packed with 5 µM SAX; SEPAX technologies, Neward, DE). Peptides were 
eluted from first and second dimensions using solutions of acetonitrile and ammonium formate 
(pH 10), trapped on the final dimension precolumn (200 µm ID fused silica x 4 cm of POROS 
10R2) after in-line dilution with 0.1% formic acid, resolved on an analytical column (25 µm ID 
fused  silica  packed  with  100  cm  of  5  µm  Monitor  C18  (Column  Engineering,  Ontario,  CA),        
2–50% B in 580min, A=0.1% formic acid, B=acetonitrile with 0.1% formic acid) and subjected to 
MS/MS (5600 Triple TOF mass spectrometer, ABI, Framingham, MA). Replicate analyses were 
performed each with 8 total fractions. 
Data Analysis. Raw mass spectrometry data files were converted to .mgf using ABSciex MS 
Data  Converter  version  1.3  and  searched  using  Mascot  version  2.2.1  after  recalibration  of 
precursor  and  product  ions  using  multiplierz  scripts  [42,  43].  Search  parameters  specified 
precursor and product ion tolerances of 0.5 Da, trypsin specificity, up to 2 missed cleavages, 
fixed carbamidomethylation (C), variable oxidation (M) and fixed iTRAQ modification (N-term, 
K). Additional multiplierz scripts were used to filter search results to a 1% false discovery rate,  
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remove reverse database hits and identifications with mass deviations greater than 25 ppm, and 
extract iTRAQ reporter ion intensities which were corrected for isotopic impurities as well as 
minor variations in source protein concentration. Abundance ratios were derived by summing 
reporters  for  all  peptides  mapping  to  unique  genes  across  replicates,  and  only  genes 
represented by 2 or more unique peptides are reported. 
 
Measurement of Oxygen Consumption Rates in whole cells and isolated mitochondria 
Oxygen consumption rate (OCR) was measured in real time using the XF24 Extracellular Flux 
analyzer  instrument  and  the  AKOS  algorithm  v1.7.0.74  software (Seahorse  Bioscience  Inc., 
North Billerica, MA). For whole cell respirometry studies and measurement of spare respiratory 
capacity (SRC) (Figure 3.5D), cells were treated with tigecycline for 15 hr prior to seeding on 
XF24 V7 plates coated with 22.4 µg/ml of Cell-Tak (BD Bioscience) at 3x10
5 cells/well in 600 µl 
of sodium bicarbonate-free RPMI medium supplemented with standard concentrations of the 
amino acids, 10% FBS, 11.1 mM D-glucose and 4 mM L-glutamine. To adhere cells to Cell Tak 
coated plates, the plates were centrifuged at 400 rpm and incubated at 37°C for 10 min. After 
baseline  measurements,  the  following  order  of  additions  were  made  using  the  instrument’s 
individual injection ports; 2.5 µM oligomycin to determine ATP-coupled OCR, 3 µM FCCP to 
determine maximal OCR, and a combination of 1 µM Antimycin A and 2.5 µM Rotenone to 
inhibit mitochondrial respiration. SRC was deduced from the difference between maximal and 
basal OCR. 
To measure complex I and complex II activities, mitochondrial OCR was measured in 
isolated mitochondria supplied with complex I-linked substrate malate/glutamate or complex II-
linked substrate succinate as previously described [19]. Briefly, mitochondria were isolated from 
cells treated with 1 µM tigecycline for 20 hr, and OCR was measured in the presence of 5 mM 
glutamate/5 mM malate or 5 mM succinate.  Succinate was combined with 2.5 µM rotenone to 
inhibit the reverse flow of electrons to complex I. OCR values shown in Figures 3.5B and 3-S2  
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indicated  state  III  respiration,  which  was  measured  after  injection  of  2  mM  ADP  using  the 
instrument’s injection ports. 
 
Statistical analysis  
All values are presented as mean ± SEM. Statistical significance was determined using two-























The studies described in this chapter were conducted as joint efforts between Illana Stanley and 
Erik  Norberg  in  the  Danial  laboratory.  Illana  Stanley  prepared  the  isolated  mitochondria  for 
proteomics  studies  and  performed  functional  assays  to  dissect  the  effects  of  tigecycline  on 
cellular  bioenergetics  and  mitochondrial  respiration.  Erik  Norberg  performed  the  knockdown 
studies  and  worked  together  with  Illana  Stanley  on  analyses  of  the  cytostatic  and  cytotoxic 
effects of tigecycline in DLBCL cell lines and primary tumor cells. The proteomics studies were 
performed in collaboration with Jarrod Marto and Scott Ficarro. Scott Ficarro performed the 
iTRAQ analysis and worked together with Illana Stanley to identify the mitochondrial proteome 
signatures of DLBCL subsets. Margaret Shipp (DFCI) and Scott Rodig (Brigham and Women’s 
Hospital) provided the primary DLBCL biopsies, and Linfeng Chen (DFCI) assisted with Ficoll 
purification of tumor cells. Illana Stanley wrote the manuscript describing these studies, which is 
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Mitochondrial  size,  shape  and  network  architecture  are  dynamically  regulated  by  the 
processes of fusion and fission. Evidence suggests that the balance between fusion and fission 
can influence the mitochondrial capacity to utilize nutrients, and exposure to different nutrients 
can in turn lead to adaptive changes in mitochondrial dynamics. We have previously shown that 
the  B-cell  receptor  (BCR)-independent  “OxPhos”  subset  of  Diffuse  Large  B-cell  Lymphoma 
(DLBCL) displays distinct metabolic features, including a substantial and selective increase in 
fatty acid oxidation (FAO) capacity compared to other carbon substrates. As FAO provides pro-
proliferative and pro-survival benefits to OxPhos-DLBCLs, identification and characterization of 
molecular modulators of FAO may provide insights into additional targets in these lymphomas. 
The studies described in this chapter show that FAO is regulated by mitochondrial architecture. 
Specifically,  OxPhos-DLBCLs  display  a  more  fragmented  mitochondrial  network  profoundly 
distinct from BCR-DLBCLs. Remarkably, blocking mitochondrial fragmentation by inhibiting the 
mitochondrial pro-fission GTPase DRP1 blunts FAO but does not alter oxidation of other fuels, 
ruling  out  pleiotropic  effects  on  substrate  oxidation.  Notably,  mitochondrial  fragmentation 
facilitates oxidation of both long- and short-chain fatty acids, indicating that the mitochondrial 
outer membrane enzyme carnitine palmitoyl transferase (CPT)1, which is specifically required 
for the import of long-chain fatty acids, is not the main site of FAO regulation by mitochondrial 
fragmentation. Consistent with its effects on FAO, inhibition of mitochondrial fragmentation is 
selectively toxic to OxPhos-DLBCLs but does not affect the viability of BCR-dependent DLBCLs. 
Overall,  these  findings  point  to  a  specific  requirement  for  mitochondrial  fragmentation  in 







Mitochondria are distributed as a network throughout the cytoplasm with specific sizes, shapes 
and  degrees  of  interconnectedness.  These  properties  are  regulated  by  the  competing 
processes of fusion and fission, controlled by large GTPases at the mitochondrial outer and 
inner  membranes.  Mitochondrial  fragmentation  by  fission  is  primarily  executed  by  Dynamin-
related  protein  1  (DRP1),  a  cytosolic  protein  that  is  recruited  to  the  mitochondrial  outer 
membrane  at  points  of  future  membrane  constriction  [1].  The  recruitment  of  DRP1  to  the 
mitochondrial  membrane  is  likely  mediated  and/or  regulated  by  one  or  more  integral 
mitochondrial outer membrane proteins such as FIS1 (Fission protein 1), MFF (Mitochondrial 
fission factor) and MiD49/MiD51 [2] (Figure 4.1). Fusion is orchestrated by mitofusins (MFN) 1 
and 2 in the outer mitochondrial membrane and the optic atrophy 1 (OPA1) protein in the inner 
mitochondrial membrane [3] (Figure 4.1).  
While early reports implicated the fragmented vs. connected state of the mitochondrial 
network  in  the  regulation  of  cell-death/apoptotic  mechanisms  [4-7],  recent  work  suggests  a 
broader role for mitochondrial dynamics as a general homeostatic mechanism for changes in 
nutrient utilization and energy demand [8]. This is in turn linked to the capacity of fusion and 
fission  factors  to  integrate  signals  from  external  and  internal  stimuli  to  adapt  mitochondrial 
morphology  to  the  changing  needs  of  the  cell.  For  example,  during  complete  starvation 
conditions, the inhibitory phosphorylation of DRP1 by cAMP dependent protein kinase A (PKA) 
at Ser637 generates hyperfused mitochondria that are spared from autophagic degradation [9]. 
Conversely, excess nutrient overload leads to mitochondrial fragmentation in pancreatic β-cells 
as a protection against apoptosis induced by glucolipotoxicity [10]. It is likely that modulation of 
nutrient utilization capacity by mitochondrial architecture occurs through multiple control points, 
including the organization and assembly of electron transport chain components [11], as well as 
mitochondrial  nutrient  access  and  import.  The  precise  regulation  of  these  processes  by 









Figure 4.1. Protein mediators of fusion and fission 
Illustration of the competing processes of fission (left) and fusion (right). Fission is mediated 
by the recruitment of cytosolic DRP1 to the outer mitochondrial membrane. MFF, FIS1 and 
MiD49/51 are proteins tethered to the outer mitochondrial membrane, which play a role in 
recruiting DRP1 to the outer membrane. DRP1 GTPase activity leads to constriction of one 
mitochondrion into two. This activity is inhibited by the small molecule mdivi-1. Fusion of the 
outer membrane is mediated by MFN1 and 2 GTPases, which form oligomers that connect 
two  mitochondria  before  fusion  and  mediate  merging  of  the  outer  membranes.  Inner 
membrane fusion is regulated by the IMM protein OPA1. 
Abbreviations:  Dynamin  related  protein  1  (DRP1),  Mitochondrial  fission  factor  (MFF), 
Mitofusin  (MFN)  1  and  2,  Outer  mitochondrial  membrane  (OMM),  Inner  mitochondrial 
membrane (IMM).  
! 105 
As described in Chapter 2, we recently characterized distinct patterns of fuel utilization 
capacity and associated metabolic dependencies in two genetic subsets of Diffuse Large B-Cell 
Lymphoma  (DLBCL).  In  particular,  OxPhos-DLBCLs  display  elevated  mitochondrial  electron 
transport chain (ETC) activity and ATP production, as well as greater incorporation of fatty acid-
derived carbons into the tricarboxylic acid (TCA) cycle [12]. These tumors survive independent 
of B-cell receptor (BCR) signalling, which is important for the activation and maintenance of 
normal  B-lymphocytes  and  for  the  survival  of  the  BCR-dependent  DLBCL  subtype  [13-16]. 
Instead, OxPhos-DLBCLs rely on mitochondrial fatty acid oxidation (FAO) for proliferation and 
survival [12]. Early dissection of pathways that could contribute to enhanced FAO in OxPhos-
DLBCLs identified a role for PPARγ, a transcriptional regulator of fatty acid oxidation enzymes 
that  contributes  to  the  survival  of  OxPhos-DLBCLs  [12].  However,  it  is  likely  that  additional 
pathways  promote  FAO  in  OxPhos-DLBCLs.  Identification  of  these  pathways  may  not  only 
provide  molecular  insights  into  regulation  of  FAO,  but  also  uncover  additional  strategies  to 
interfere with FAO-dependent survival. The studies reported in this chapter have identified a 
functional link between mitochondrial architecture, in particular a more fragmented mitochondrial 
network, and FAO in OxPhos-DLBCLs.  
 
RESULTS 
OxPhos-DLBCLs maintain a more fragmented mitochondrial network  
To  examine  whether  the  distinct  fuel  utilization  patterns  in  DLBCL  subtypes  are 
associated with changes in mitochondrial morphology, the mitochondrial network was examined 
in a panel of four OxPhos- and four BCR-DLBCL cell lines that were fixed and stained with the 
mitochondrial potentiometric dye Mitotracker Red. Mitochondria appeared smaller in OxPhos-
DLBCL cell lines compared to large globular mitochondria observed in BCR-DLBCL cell lines 










Figure  4.2.  OxPhos-  and  BCR-DLBCL  cell  lines  have  distinct  mitochondrial 
morphologies 
(A) Representative images of the mitochondrial network in OxPhos- and BCR-DLBCL cell 
lines labeled with Mitotracker Red. Each image displays maximum intensity projections of 
0.25 µm interval Z-stacks displaying the mitochondrial network within a single representative 
cell. (B) Quantification of mean mitochondrial area per cell for four OxPhos- and four BCR-
DLBCL  cell  lines.  Error  bars,  ±  SEM.  ***p  <  0.001;  two-tailed  Student’s  t-test.  (C) 
Representative confocal images of live cells expressing the matrix targeted dsRed, which 
were immobilized in low percentage agarose before imaging. 
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Careful  quantification  of  mean  mitochondrial  cross-sectional  area  per  cell  indicated  that  the 
average mitochondrial area was significantly reduced in OxPhos-DLBCL cell lines compared to 
BCR counterparts (Figure 4.2B). Moreover, similar observations were made in live cells upon 
labeling  mitochondria  with  matrix-targeted  dsRed  (mt-dsRed)  or  the  membrane  potential 
sensitive dye TMRE, indicating that the observed morphologic differences were not an artifact of 
fixation (Figure 4.2C and data not shown). These data suggest that the mitochondrial network in 
OxPhos-DLBCLs may be more fragmented, which can in turn stem from changes in the net 
balance of mitochondrial fusion and fission, including increased relative rates of fission over 
fusion.  
 
Genetic  and  pharmacologic  inhibition  of  mitochondrial  fission  blocks  mitochondrial 
fragmentation and perturbs FAO in OxPhos-DLBCLs 
Given that the fragmented mitochondrial network was restricted to OxPhos-DLBCLs and 
was not observed in BCR-DLBCLs, a possible connection between mitochondrial morphology 
and  FAO,  which  is  a  prominent  metabolic  feature  of  OxPhos-DLBCLs  [12],  warranted 
investigation.  This  was  initially  addressed  by  examining  palmitate  oxidation  in  OxPhos-  and 
BCR-DLBCL  cell  lines  in  which  the  pro-fission  protein  DRP1  was  inhibited  using  the  K38A 
dominant-negative  DRP1  mutant  (DRP1-DN)  [17].  As  expected,  expression  of  DRP1-DN,  in 
both OxPhos- and BCR-DLBCL cell lines, led to a more fused mitochondrial network (Figure 
4.3A).  This  was  associated  with  reduced  FAO  in  OxPhos-DLBCLs  as  measured  by 
mitochondrial respiration rates in response to palmitate (Figure 4.3B,C). Expression of DRP1-
DN in BCR-DLBCL cell lines did not alter FAO (Figure 4.3B,C). To provide a pharmacologic 
correlate to the effect of DRP1-DN on FAO, a small molecule inhibitor of DRP1 GTPase activity, 
mdivi-1 [18], was also examined. Similar to DRP1-DN, 24 hr treatment with mdivi-1 led to a 





















Figure 4.3. Inhibition of DRP1 selectively reduces FAO capacity in OxPhos-DLBCLs 
(A)  Representative  confocal  images  of  OxPhos-  and  BCR-DLBCL  cell  lines  expressing       
DRP1-DN  in  which  mitochondria  were  labeled  with  Mitotracker  Red.  Maximum  intensity 
projections of 0.25 µm interval z-stacks are shown. (B-C) Mitochondrial oxygen consumption 
rates (OCR) on palmitate in DLBCL cell lines expressing DRP1-DN. (B) Representative OCR 
traces are shown for one OxPhos-DLBCL (Pfeiffer) and one BCR-DLBCL (SU-DHL-4) cell 
line.  Dotted  line  indicates  time-point  of  oligomycin  injection. Representative western  blots 
showing the level of DRP1-DN in the same cell lines are shown on top. (C) Cumulative data 
for ATP-coupled OCR in two OxPhos-DLBCL (Pfeiffer and OCI-Ly4) and one BCR-DLBCL 
(SU-DHL-4) cell line deduced from similar traces as in (B), n=2 independent experiments per 
cell line. All analyses were performed 24 hr after infection with lentiviruses carrying DRP1-












Figure 4.4. A chemical inhibitor of DRP1 reduces FAO and viability in OxPhos-DLBCLs  
(A) ATP-coupled oxygen consumption rates (OCR) in response to palmitate in the indicated 
DLBCL cell lines following 24 hr treatment with mdivi-1 with the indicated concentrations, n=3 
independent experiments per condition (B) Survival of DLBCL cell lines treated for 48 hr with 
10-30 µM mdivi-1. Asterisks in (B) compare the BCR-DLBCL cell line to both OxPhos-DLBCL 
cell  lines,  n=3  independent  experiments  per  condition  Error  bars,  ±  SEM.  *p  <  0.05;             
**p < 0.01; two-tailed Student’s t-test. 
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Because FAO contributes to the survival of OxPhos-DLBCLs [12], blocking mitochondrial 
fragmentation and the attendant reduction in FAO is predicted to be toxic to this subtype over 
longer periods of time. Low infection efficiency of DLBCL cell lines precluded examination of 
long-term  effects  of  DRP1-DN.  For  this  reason,  we  investigated  the  outcome  of  mdivi-1 
treatment on DLBCL survival. A selective and dose-dependent diminution of cell viability was 
apparent  in  OxPhos-DLBCL  cell  lines  following  48  hr  treatment  with  mdivi-1  (Figure  4.4B). 
These results suggest that maintaining a fragmented mitochondrial network may be relevant to 
OxPhos-DLBCL survival by supporting/promoting FAO.  
 
Regulation of fuel oxidation by mitochondrial fragmentation is selective for fatty acids 
and independent of fatty acid chain length 
To  determine  if  inhibition  of  fission  has  a  pleiotropic  effect  on  mitochondrial  fuel 
oxidation, we compared mitochondrial oxidation of glutamine in the presence or absence of 
DRP1-DN. We have previously shown that both DLBCL subtypes are capable of respiring on 
glutamine  (Chapter  2,  Figure  2.4).  In  contrast  to  its  effect  on  FAO,  DRP1-DN  did  not  alter 
mitochondrial  handling  of  glutamine  (Figures  4.5  and  4-S2).  Thus,  in  this  setting,  the 
contribution of mitochondrial fragmentation to fuel oxidation appears to be selective for fatty 
acids. However, additional studies are required to expand the spectrum of respiratory substrates 
examined in these experiments.  
Because blocking mitochondrial fragmentation inhibits FAO but does not alter oxidation 
of glutamine, the effect of mitochondrial morphology on FAO is less likely to occur  through 
regulation of the TCA cycle or respiratory chain activity per se. For this reason, we turned our 
attention to fatty acid import from the cytoplasm to the mitochondrial matrix where the enzymes 



















Figure  4.5.  Blocking  fragmentation  reduces  oxidation  of  fatty  acids  but  not  other 
carbon substrates 
ATP-coupled  mitochondrial  oxygen  consumption  rates  (OCR)  in  response  to  0.2  mM 
palmitate,  0.5  mM  hexanoate  or  2  mM  L-glutamine  24  hrs  after  lentiviral  transduction  of 
DRP1-DN . Cumulative data from three independent experiments in two OxPhos-DLBCL cell 




Long chain fatty acids such as palmitate require conjugation to carnitine via carnitine palmitoyl 
transferase (CPT)1 for transport across the mitochondrial inner membrane while short chain 
fatty acids are able to passively diffuse across the inner membrane [19]. We reasoned that if 
CPT1 is a step where mitochondrial fragmentation exerts its effect, then DRP1-DN expression 
should selectively affect oxidation of palmitate but not hexanoate, a short chain fatty acid. If, 
however, oxidation of both long- and short-chain fatty acids is modulated by DRP1-DN, CPT1 is 
less likely to be the main point of regulation by fragmentation. Parallel comparison of palmitate 
and hexanoate oxidation in OxPhos-DLBCLs indicated a comparable reduction in the presence 
of DRP1-DN (Figures 4.5 and 4-S2). Thus, the mechanism underlying regulation of FAO by 
mitochondrial fragmentation is likely independent of CPT1. 
 
DISCUSSION 
The  findings  described  in  this  chapter  are  consistent  with  a  model  in  which  a  more 
fragmented mitochondrial network is required for maintaining high FAO capacity in OxPhos-
DLBCLs.  As  such,  this  chapter  highlights  distinctions  in  mitochondrial  architecture  as  a 
previously unappreciated dimension to the differences in fuel utilization patterns we previously 
described in DLBCL subsets. These observations give rise to several questions that are the 
subject  of  ongoing  studies,  including  the  underlying  cause  of  the  fragmented  mitochondrial 
network in OxPhos-DLBCLs and the mechanism by which it facilitates FAO.   
At the molecular level, it is likely that differences in regulation of pro-fusion and pro-
fission GTPases in the two DLBCL subtypes may shift the net balance between fusion and 
fission  toward  increased  fission  in  OxPhos-DLBCLs  and  elevated  fusion  in  BCR-DLBCLs. 
Consistent with this idea, the enlarged round mitochondria observed in BCR-DLBCLs resemble 
“mitochondrial bulb” structures reported in HeLa cells following depletion of DRP1 or MFF and 
the resulting block in fission [20-22]. Efforts are underway to distinguish between these potential  
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scenarios by directly measuring fusion and fission rates in real time upon co-labeling individual 
mitochondria with matrix-targeted photo-activatable GFP (mtPAGFP) and TMRE [23].  
We  predict  that  potential  differences  in  relative  fusion  and  fission  rates  between  the 
DLBCL subsets may in turn be linked to differential regulation of the protein machinery in charge 
of modifying the mitochondrial architecture, including the DRP1, OPA1, and MFN1/2 GTPases. 
These  differences  may  manifest  at  the  level  of  protein  abundance  or  post-translational 
modifications  (PTMs)  capable  of  modulating  their  activity,  protein-protein  interactions,  and 
mitochondrial  localization.  Such  modifications  include,  phosphorylation  (DRP1)  [9,  24,  25], 
ubiquitination  (DRP1,  FIS1  and  MFN2)  [26-28],  S-nitrosylation  (DRP1)  [29],  O-GlcNAc 
modification (DRP1) [30], and SUMOylation (DRP1) [31]. These PTMs can allow remodelling of 
the  mitochondrial  network  architecture  in  response  to  a  diverse  array  of  cellular  cues  and 
signaling  modules  [9,  25,  28].  In  the  context  of  DLBCL-subtypes,  one  potential  candidate 
pathway is signaling downstream of the B-cell receptor, a signaling axis that distinguishes the 
two DLBCL subtypes, and normally inhibits FAO in BCR-DLBCLs (Chapter 2, Figure 2.4B) [12].  
Another possible mechanism that would support increased mitochondrial fragmentation 
in OxPhos-DLBCLs is altered regulation of the factors that recruit DRP1 to the mitochondrial 
outer  membrane,  including  MFF  [20,  32].  Previous  biochemical  studies  and  genetic  rescue 
experiments have shown that regulation of MFF protein stability by the HSP90 family protein 
TRAP1 is an important determinant of mitochondrial network fragmentation [33]. Interestingly, 
TRAP1  is  enriched  in  mitochondria  isolated  from  OxPhos-  compared  with  BCR-DLBCLs  as 
evident from quantitative proteomics [12] and western blot analysis (Figure 4-S3). This predicts 
MFF  protein  may  be  more  stable  in  OxPhos-DLBCLs,  potentially  resulting  in  increased 
recruitment of DRP1 to mitochondria and greater fission. This possibility remains to be formally 
tested.  
A novel and unexpected finding in our studies is the selective effect of mitochondrial 
fission  on  mitochondrial  handling  of  fatty  acids  as  opposed  to  other  fuels.  The  molecular  
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underpinnings of this fuel-selective effect are currently unknown. Our data do not support CPT1 
and  the  mitochondrial  import  of  long-chain  fatty  acids  as  the  main  site  of  regulation  by 
fragmentation.  It  is  possible  that  the  smaller  mitochondrial  size  facilitates  mitochondrial 
juxtaposition near lipid droplets, where fatty acids are stored as triglycerides or activated to their 
fatty acyl-CoA derivatives and oxidized in the mitochondria [34, 35]. This mechanism, which can 
directly influence the access of mitochondria to fatty acids, has been predominantly studied in 
brown adipocytes, a cell type that is normally enriched in lipid droplets and oxidizes fatty acids 
extensively. Whether a similar mechanism operates in other cell types is not known. Notably, 
lipid droplets can be detected in OxPhos- and BCR-DLBCL cell lines (Figure 4-S4). Whether 
juxtaposition of mitochondria near lipid droplets is quantitatively different in OxPhos- and BCR-
DLBCLs warrants examination.  
Overall,  our  findings  indicate  engagement  of  additional  regulatory  pathways  that 
influence  the  FAO  capacity  and  its  effect  on  DLBCL  survival.  Here,  we  have  identified 
mitochondrial network dynamics and architecture as one such regulatory pathway that provides 
an  additional  component  to  the  metabolic  distinction  between  OxPhos-  and  BCR-DLBCLs. 
Understanding  the  molecular  dialogue  between  FAO  and  mitochondrial  architecture  may 
provide  novel  insights  into  fuel  utilization  pathways  in  DLBCLs  that  may  be  therapeutically 
exploited. Such insights may also have broader implications for molecular regulation of FAO in 









MATERIALS AND METHODS 
Cell culture 
All DLBCL cell lines were grown in RPMI-1640 supplemented with 10% fetal bovine serum,  
2 mM L-glutamine, and 1% penicillin/streptomycin as described in Chapter 2.  
 
Western blots 
Whole cell lysates were analyzed by 4-12% BisTris NuPage (Invitrogen) gel electrophoresis, 
transferred to nitrocellulose membrane, and developed with antibodies against DRP1 (Abcam 
ab56788) or β-Tubulin (Millipore 05-661).  
 
Expression of DRP1-DN in DLBCL cell-lines 
The lentiviral vector expressing the K38A dominant mutant of DRP1 was a generous gift of Dr. 
Orian Shirihai (Boston University). Lentiviral supernatants were generated by standard lentivirus 
packaging techniques in HEK 293 cells and used to transduce DLBCL cell lines by “spinfection”. 
Briefly, 5x10
5 cells were centrifuged in 5-8 ml of viral supernatant for 2 hr at 460 g at room 
temperature. Subsequent metabolic assays were done 24 hr after infection.  
 
Mdivi-1 viability assay 
Cells were seeded at 2.5x10
5 cells/ml and treated with 10-30 µM of mdivi-1 (Sigma) or vehicle 
(DMSO)  control  for  24  hr.  Cell  viability  was  analyzed  using  the  Annexin  V/FITC  Apoptosis 
Detection Kit (BD Bioscience) by flow cytometry.   
 
Imaging and quantification of mitochondrial morphology 
DLBCL cell lines were stained with 100 nM Mitotracker Red™ (Invitrogen) for 15 min at 37°C, 
washed in PBS, and incubated for an additional 15 min at 37°C on poly-l-lysine coated glass  
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coverslips.  Cells  were  then  fixed  in  4%  paraformaldehyde  for  30  min  at  room  temperature. 
Coverslips were then mounted on glass slides using mounting media (Vectashield) and sealed 
with clear nail polish. Cells were imaged using the 100x objective of a Zeiss LSM 710-Live Duo 
Scan  confocal  microscope.  30-40  consecutive  Z-stacks  were  taken  at  0.25  µm  intervals 
covering the height of an entire cell. Mitochondrial area was quantified using ImageJ 1.47f. For 
imaging of mitochondrial morphology in live cells, Pfeiffer and SU-DHL-4 cell lines were infected 
with lentiviruses carrying mt-dsRed [23] at an MOI of 5 and immobilized in 0.5% agarose/phenol 
red-free DMEM on MatTek plates. Images were collected on a Zeiss LSM 710-Live Duo Scan 
confocal  microscope  using  a  humidified  chamber  supplied  with  5%  CO2  and  maintained  at 
37°C. 
 
Measurement of oxygen consumption 
Mitochondrial oxygen consumption rates (OCR) were measured in real time using the XF24 
Extracellular Flux analyzer instrument and the AKOS algorithm v1.7.0.74  software (Seahorse 
Bioscience Inc., North Billerica, MA). Briefly, 24 hr after lentiviral transduction of DRP1-DN or 
treatment with mdivi-1, cells were seeded in XF24 V7 plates coated with 22.4 µg/ml Cell Tak 
(BD  Bioscience)  at  a  density  of  3x10
5  cells  in  600  µl  of  sodium  bicarbonate-free  RPMI 
supplemented  with  0.2  mM  palmitate/0.5  mM  carnitine,  0.5  mM  hexanoate,  or  2  mM                 
L-glutamine. OCR was measured for 3 min periods with 5 min intervals between consecutive 
measurements.  To  measure  ATP-coupled  respiration,  oligomycin  was  injected  at  a  final 






Statistical Analysis  
All values are presented as mean ± SEM. Statistical significance was determined using two-
tailed Student's t-test assuming unequal variance. Significance indicated by p-values as follows: 
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The investigation of metabolic profiles in DLBCL subsets has revealed several functional 
distinctions in the OxPhos subtype compared to the BCR-dependent subtype, including reliance 
on  elevated  ETC  activity,  FAO,  the  mitochondrial  translation  pathway,  and  a  fragmented 
mitochondrial  network  architecture.  Comparison  of  glucose  and  non-glucose  fuel  utilization 
pathways and mitochondrial bioenergetics in these two DLBCL subsets provided insights into 
the degree of metabolic heterogeneity that may exist within a given cancer type and alternative 
metabolic programs to aerobic glycolysis. The findings described in the previous chapters have 
also given rise to additional hypotheses and research opportunities that will lay the foundation 
for  future  investigations,  three  of  which  are  highlighted  in  the  following  sections;  the  link 
between  metabolic  profiles  of  DLBCL  subsets  and  normal  developing  B  lymphocytes,  the 
molecular pathways that contribute to higher ETC activity but lower ROS content in OxPhos-
DLBCLs, and therapeutic implications of metabolic distinctions identified in DLBCL subsets.  
 
The  potential  connection  between  metabolic  profiles  of  DLBCL  subtypes  and  normal 
developing B lymphocytes 
  One of the questions arising from this work is whether the metabolic profiles of DLBCL 
subtypes are acquired de novo during lymphomagenesis or they resemble certain metabolic 
features of normal B lymphocyte subsets. DLBCLs arise from germinal centers (GCs), a site of 
B-cell development where mature B-cells are activated upon encountering their cognate antigen 
and signals from T-cells [1]. Upon activation, germinal center B-cells can have several distinct 
fates. They can rapidly divide as centroblasts and subsequently undergo apoptosis or further 
differentiate into antibody secreting plasma cells or non-secreting memory B-cells that can be 
activated to produce antibodies upon antigen re-exposure [1]. These developmental cell fates 
are regulated by complex arrays of transcription factors and signaling pathways [2]. Because B-
cell  activation  in  the  GCs  is  further  linked  to  immunoglobulin  class  switching  and  somatic 
hypermutation,  two  processes  that  involve  DNA  modifications  and  chromosomal  breaks  to  
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modify the BCR’s affinity for antigens, the GC phase of B-cell development is especially prone 
to mutations and chromosomal translocations leading to lymphomagenesis. While the precise 
origin of DLBCLs in the GC is debated, highly proliferating centroblasts and plasmablasts have 
been proposed as putative origins [2]. This suggests that DLBCLs may share certain features of 
a normal germinal center B-cell differentiation program.  
  The different stages of germinal center B-cell development, including proliferation, DNA 
modifications,  antibody  production  and  secretion,  are  bioenergetically  and  biosynthetically 
demanding  processes.  The  exact  metabolic  profile  of  naïve  (antigen-inexperienced)  and 
activated  (antigen-experienced)  B-cells  or  long-term  antibody  producing  plasma  cells  and 
memory B-cells are debated. Comparative metabolomics revealed that naïve B-cells perform 
oxidative phosphorylation, and following engagement of their BCR by antigen, they switch to 
aerobic  glycolysis  [3].  The  Warburg-type  profile  of  activated  B-cells  is  consistent  with  the 
metabolic characteristics of many proliferating cell types and the metabolic switch associated 
with  the  transition  from  a  quiescent  to  proliferative  state  [4,  5].  This  might  also  parallel  the 
Warburg-type  metabolic  profile  of  BCR-DLBCLs  (Chapter  2,  Figures  2.8A  and  2.11)  and  is 
further  consistent  with  published  reports  that  BCR-stimulation  of  normal  B-cells  leads  to  a 
PI3K/AKT-dependent up-regulation of glucose uptake and glycolysis [6]. A switch from oxidative 
phosphorylation  to  aerobic  glycolysis  has  also  been  reported  in  the  transition  of  naïve  to 
activated T lymphocytes [7-9]. Notably, oxidative phosphorylation in naïve T-cells is linked to 
increased FAO [10], but increased FAO has not been reported in naïve B-cells. A recent study 
has revealed a more complex landscape of metabolic pathways in activated B-cells, suggesting 
that,  unlike  activated  T-cells,  activated  B-cells  demonstrate  a  concomitant  up-regulation  of 
glycolysis and oxidative phosphorylation [11]. Specifically, the rate of glycolysis is higher in B-
cells  than  T-cells,  and  following  B-cell  activation,  oxidative  phosphorylation  is  proportionally 
increased. The precise substrates oxidized by mitochondria in this setting (glucose, fatty acids, 
amino  acids)  have  not  yet  been  determined.  In  addition,  if  and  how  the  balance  between  
! 126 
glycolysis and oxidative phosphorylation changes once activated B-cells further differentiate to 
plasma  or  memory  cells  merits  future  examination.  Within  this  context,  the  metabolic 
requirements  of  antibody  production  by  plasma  cells  are  likely  complex.  While  glucose 
metabolism has been shown to be important [11], the physiologic contribution of mitochondrial 
pathways  to  antibody  production  has  not  been  determined.  This  is  especially  relevant  as 
mitochondrial function can affect the calcium and energy requirements of the secretory pathway 
and release of antibodies. Consistent with this idea, a previous study showed that, PPARγ, 
which can activate the expression of oxidative phosphorylation and FAO genes, is important for 
antibody production by B-cells [12].  
While BCR-DLBCLs appear to be metabolically similar to activated B-cells in terms of 
aerobic glycolysis, it is unclear which stages of germinal center B-cell differentiation might be 
most similar to the metabolic features of OxPhos-DLBCLs. Similar to naïve B-cells, OxPhos-
DLBCLs display increased oxidative phosphorylation. At the same time, the lack of a functional 
BCR  in  these  lymphomas  is  reminiscent  of  anergic  B-cells  that  are  desensitized  to  BCR 
engagement  [11,  13].  Yet,  unlike  anergic  B-cells,  OxPhos-DLBCLs  have  high  metabolic 
capacity. Knowledge of the precise metabolic alterations occurring as mature B-cells enter and 
develop  through  the  germinal  center  will  help  expand  the  metabolic  landscape  of  B-cell 
development and identify potential metabolic characteristics that might be shared with OxPhos-
DLBCLs. 
 
Additional mitochondrial homeostatic pathways that may help maintain high ETC activity 
and low ROS in OxPhos-DLBCLs  
The  reliance  of  OxPhos-DLBCLs  on  mitochondrial  metabolism,  and  specifically 
increased ETC activity, for a significant portion of overall cellular energy budget (Chapter 2, 
Figures 2.9A and 2.11A), together with up-regulation of the mitochondrial translation pathway 
necessary for synthesis of mtDNA-encoded ETC subunits (Chapter 3, Figure 3.2), point to the  
! 127 
paramount importance of ETC function in OxPhos-DLBCLs. Remarkably, increased ETC activity 
in this subtype is not associated with higher cellular mitochondrial superoxide content (Chapter 
2,  Figure  2.12A),  which  is  otherwise  expected  due  to  increased  electron  transfer  reactions. 
Lower ROS content can, in part, be explained by higher antioxidant mechanisms as indicated by 
greater GSH content and increased expression of several antioxidant enzymes such as SOD2 
in OxPhos-DLBCLs, and the observation that interference with ROS detoxification is selectively 
toxic  to  OxPhos-DLBCLs  (Chapter  2,  Figure  2.12C).  However,  because  steady  state  ROS 
content reflects the net balance of ROS production and detoxification, it is also possible that 
lower mitochondrial ROS in OxPhos-DLBCLs is reflective of highly efficient mitochondria that 
generate  less  ROS  while  harboring  high  ETC  activity.  To  help  address  this  possibility,  two 
mitochondrial  homeostatic  mechanisms  merit  consideration:  organization  of  ETC  complexes 
into  supercomplexes  that  are  more  efficient  at  electron  transport,  and  prompt  clearance  of 
inefficient or damaged mitochondria from the mitochondrial network through mitophagy.  
 
The  bioenergetic  benefits  of  ETC  supercomplexes.  ETC  complexes  were  traditionally 
thought to be individually embedded in a fluid mitochondrial membrane, interacting by random 
diffusion. However, this traditional view has been revised based on findings over the last decade 
that the ETC complexes are capable of forming higher order structures to facilitate electron flow 
by substrate channeling. Complexes I, III and IV can be found in respiratory supercomplexes 
(RSCs)  that  are  dedicated  to  NADH-linked  oxidation.  Complex  II  is  not  found  in  such 
supercomplexes  and  is  dedicated  to  FADH2-linked  oxidation  [14].  Different  carbon  fuels 
generate  different  ratios  of  reducing  equivalents.  For  example,  glucose  oxidation  generates 
more NADH, while FAO generates more FADH2, and there is evidence that assembly of the 
supercomplexes can be regulated to optimize nutrient utilization [15]. It has also been shown 
that incorporation of ETC complexes in RSCs reduces the amount of mitochondrial superoxide 
generated by complex I, suggesting that RSC formation is relevant for reduction of oxidative  
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stress [16]. Whether differences in RSC formation can contribute to increased ETC activity while 
lowering mitochondrial superoxide production in OxPhos-DLBCLs warrants future investigation.   
 
Mitochondrial quality control through mitophagy. Mitophagy, the selective degradation of 
damaged mitochondria by autophagy, is a mitochondrial quality control mechanism that lowers 
the cellular mitochondrial superoxide levels and maintains efficient oxidative phosphorylation 
[17-19],  both central metabolic characteristics of OxPhos-DLBCLs.  Mitophagy is coordinated 
with mitochondrial fusion/fission dynamics [20]. Specifically, mitochondrial fission helps “pinch 
off”  damaged  mitochondria  from  the  rest  of  the  mitochondrial  network.  In  addition,  the 
mechanisms of fusion are dependent upon respiratory function and mitochondrial membrane 
potential [20]. Damaged mitochondria have lower membrane potential and are fusion deficient, 
and are therefore prevented from fusing back with the healthy mitochondrial pool. Mitophagy 
completes  this  clearance  process  by  degrading  damaged  mitochondria,  thus  removing  and 
recycling mitochondrial components as well as preventing the increased ROS generation that 
can  occur  in  a  damaged  respiratory  chain  or  suboptimal  mitochondrion  [21].  Several  initial 
observations are consistent with the likelihood of increased mitophagy in OxPhos- compared to 
BCR-DLBCLs. First, autophagic flux is elevated in OxPhos-DLBCL cell lines compared to cells 
of  the  BCR  subtype.  Importantly,  inhibition  of  autophagy  leads  to  higher  accumulation  of 
mitochondrial superoxide and selective death of OxPhos-DLBCL cell lines without affecting the 
survival  of  BCR-DLBCLs  (Stanley  and  Danial,  unpublished  observations).  Second,  co-
localization  of  LC3-II  and  mitochondria,  an  indication  of  mitochondrial  localization  to 
autophagosomes,  tends  to  be  greater  in  OxPhos-DLBCLs.  Third,  a  potential  increase  in 
mitophagy  would  be  consistent  with  smaller  mitochondrial  surface  area  and  a  fragmented 
mitochondrial network in OxPhos-DLBCLs (Chapter 4, Figure 4.2), which can be easily engulfed 
by  autophagosomes.  This  warrants  a  more  thorough  investigation  of  the  contribution  of  
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mitophagy to increased ETC efficiency, diminished intracellular ROS content, and survival of 
OxPhos-DLBCLs. 
 
Potential therapeutic implications 
Given the genetic and clinical heterogeneity of DLBCL, strategies to stratify patients, 
predict chemotherapeutic response, identify diagnostic markers and discover subtype-selective 
therapeutic  targets  will  greatly  improve  DLBCL  therapy  and  management.  By  identifying, 
characterizing  and  testing  the  contribution  of  metabolic  pathways  relevant  to  DLBCLs,  in 
particular  the  BCR-independent/OxPhos  subtype  of  DLBCL,  the  work  described  in  this 
dissertation  has  the  potential  to  unravel  novel  therapeutic  targets,  as  well  as  resistance 
mechanisms to current therapies aimed at BCR initiated survival signaling that are normally 
operative  in  BCR-dependent  DLBCLs.  Furthermore,  given  that  the  BCR  signaling  pathway 
includes canonical pro-survival signaling nodes such as PI3K/AKT and mTOR that are highly 
relevant to a number of other cancer types, BCR-independent survival mechanisms may have 
broader implications to other tumors.  
 
Targeted  therapies  and  resistance  mechanisms  to  BCR  inhibition.  Identification  and 
characterization of molecular signatures in DLBCLs has provided great insights into both the 
molecular  pathogenesis  of  these  tumors  as  well  as  targetable  pathways.  To  date  such 
molecular  signatures  have  been  predominantly  based  on  gene  expression  profiling  and 
associated  mutations/chromosomal  alterations  that  have  uncovered  dominant  survival 
mechanisms  in  DLBCL  [2,  22-24].  Among  these,  the  BCR  signaling  axis  and  the  genetic 
alterations  that  lead  to  increased  activity  of  its  downstream  components,  including  NF-κB, 
PI3K/AKT, SYK and BTK, are actively pursued for their therapeutic utility in BCR-dependent 
DLBCLs.  The  BCR-independent  survival  characteristics  of  OxPhos-DLBCLs  renders  them 
refractory to BCR inhibition. The work described in this dissertation has begun to characterize  
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BCR-independent survival signaling that, in the fullness of time, may be therapeutically relevant. 
In particular, certain small molecule inhibitors of FAO and the mitochondrial translation pathway 
are approved for use in cancer or other disease indications [25-28]. Importantly, the findings that 
acute  inhibition  of  BCR  signaling  in  BCR-DLBCLs  is  sufficient  to  increase/disinhibit  FAO 
indicates  a  reciprocal  relationship  between  BCR  signaling  and  FAO.  As  FAO  can  provide 
proliferation  and  survival  benefits  independent  of  the  BCR,  these  observations  may  have 
broader implications for lymphomas that have lost dependency on the BCR pathway or acquired 
resistance to inhibitors of this signaling axis. As such, dissection of the molecular link between 
BCR signaling and FAO will likely provide valuable insights.  Thus,  characterization of BCR-
independent  survival  mechanisms  will  not  only  be  relevant  to  understanding  the  molecular 
pathogenesis of OxPhos-DLBCLs but also unravel potential resistance mechanisms to BCR-
targeted interventions.  
 
Diagnostic utility of metabolic distinctions in DLBCL subtypes. In light of the metabolic 
distinctions in DLBCL subtypes with respect to glucose and fatty acid metabolism, investigation 
of  the  utility  of  glycolysis  and  FAO  probes  for  diagnostic  and  functional  imaging  of  DLBCL 
subtypes is warranted. FDG-PET imaging is routine in clinical care for DLBCLs. The selectivity 
of 
18F-FDG-PET for cancer over normal tissue is due to increased glucose metabolism in many 
tumors  [29].  Previous  analyses  of  FDG  uptake  revealed  a  broad  range  of  avidity  in  newly 
diagnosed DLBCLs. The possibility that BCR/Warburg-type and OxPhos-type DLBCLs differ in 
their FDG uptake may explain the broad range of FDG avidity seen in newly diagnosed DLBCL 
patients and requires investigation. As such, comparison of the FDG uptake profiles of patient 
cohorts for which CCC classification is already available with tumors designated as OxPhos- or 
BCR-type  will  be  very  informative.  Another  useful  approach  would  be  FDG-PET  imaging  of 
OxPhos- and BCR-DLBCL xenografts in mice. Based on the metabolic profiles described in 
Chapter 2, BCR-DLBCLs are predicted to be more FDG-PET avid than OxPhos-DLBCLs. In  
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addition,  FAO  imaging  probes  such  as  [
18F]fluoro-4-thia-oleate  (FTO)  [30]  may  be  tested  in 
similar settings. Based on the findings discussed in this dissertation, 
18F-FTO radioactivity is 
predicted to be higher in OxPhos-DLBCLs.  
 
A pan OxPhos metabolic signature and its broader implications in other heterogeneous 
cancers.  The  proteome-  and  metabolome-level  signatures  that  emerged  from  integrative 
metabolic analysis of DLBCL subsets expanded the original mitochondrial gene signature of 
OxPhos-DLBCLs  to  include  functionally  validated  and  biologically  relevant  pathways  of  fuel 
utilization  and  associated  vulnerabilities  in  DLBCL  subsets.  The  expanded  set  of  genes 
selectively enriched in OxPhos-DLBCLs and multiple validated functional readouts for “OxPhos-
ness” provides a unique opportunity to develop, test and validate a parsimonious classifier of 
OxPhos versus non-OxPhos distinction that may then serve as a powerful tool to interrogate 
other heterogeneous groups of tumors for the presence of similar metabolic heterogeneity and 
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Figure 2-S1. Comparison of mitochondrial proteome via 2D-DIGE 
2D-DIGE  comparison  of  mitochondria  isolated  from  Karpas  422  (OxPhos)  and  OCI-Ly1 
(BCR) DLBCL cell lines. Equivalent amounts of mitochondrial protein lysates from OCI-Ly1 
and Karpas 422 cell lines were labeled with Cy3 and Cy5 DIGE fluors, respectively, mixed 
and resolved on a 2D analytical gel (Applied Biomics, inc. Hayward, CA) (left panel). Image 
scans were carried out and the differential protein expressions (Cy5/Cy3) were determined 
using DeCyder software (version 6.5, GE-Healthcare). Proteins that were ≥ 2.5 f old more 
abundant  in  OxPhos-DLBCL  were  picked  by  Ettan  Spot  Picker  (GE-Healthcare)  and 
subjected  to  in-gel  trypsin  digestion,  peptide  extraction,  desalting,  and  MALDI-TOF/TOF 
mass spectrometry (Applied Biosystems). Protein species in red display higher abundance in 
the OxPhos-DLBCL cell line Karpas 422. pI, iso-electric point. Identity and metabolic function 



















































Figure 2-S2. iTRAQ-based quantitative comparison of DLBCL mitochondrial proteome 
Schematics of analytical work flow for multiplex iTRAQ analysis of mitochondria isolated from 
DLBCL cell lines. Mitochondria isolated from the indicated DLBCL cell lines were subjected 
to  tryptic  digestion  and  iTRAQ  labeling  and  analyzed  by  LC-MS/MS  as  described  in     
Chapter 2. MS files were searched using Mascot version 2.2.1 against a forward-reversed 
human (38190 forward entries) NCBI refseq database with an appended cRAP database of 
752 entries. An excel spreadsheet containing the Mascot search results was generated using 
Multiplierz version 0.8.3. Abundance ratios for the protein candidates within the mitochondrial 
protein signature (defined in Figure 2-S1) were derived by summing reporters for all peptides 
mapping to unique genes across replicates. Only genes represented by 2 or more unique 































Figure 2-S3. Mitochondrial carbon substrate oxidation in DLBCL subsets 
Basal (top) and ATP-coupled (bottom) OCR in individual DLBCL cell lines. For each cell line, 
the mean of 7-13 independent respirometry experiments (independent days and independent 
plates  and  cartridges  for  the  XF24  flux  analyzer  instrument)  is  shown.  NS  denotes  no 
substrate added exogenously. Cumulative data for all cell lines per subtype are shown in 











































Figure 2-S4. FAO following acute knockdown of CD79B in BCR-DLBCL cell lines 
Palmitate  stimulated  basal  OCR  in  the  indicated  non-OxPhos/BCR-DLBCL  cell  lines 
following 24 hr acute knockdown of CD79B. Error bars, ± SEM. **p < 0.01; ***p < 0.001; two-
tailed Student’s t-test. Diminished FAO in this setting can also be corroborated by another 














Figure 2-S5. Efficiency of SYK knockdown in BCR-type DLBCL cell lines   
Efficiency  of  shRNA-mediated  SYK  depletion.  SYK  protein  levels  24  hr  after  cells  were 
infected with the indicated lentiviruses. This time point was also used to analyze the effect of 










Figure 2-S6. Knockdown of PPARγ in DLBCL cell lines 
(A)  Viability  of  DLBCL  cell  lines  after  72  hr  treatment  with  individual  or  a  mixture  of                 
3 independent siRNAs against PPARγ. Error bars, ± SEM. **p <0.01; ***p < 0.001; two-tailed 
Student’s t-test. (B) Western blot analysis of PPARγ levels in DLBCL cell lines subjected to 
siRNA  as  in  (A),  showing  best  knockdown  efficiency  was  achieved  with  the  mixture  of 















Figure 2-S7. Efficiency of shRNA-mediated GCS depletion  
GCS protein levels 72 hr after the indicated DLBCL cell lines were infected with lentiviruses 




































Figure  3-S1.  Efficiency  of  shRNA-mediated  depletion  of  mitochondrial  translation 
components   
Protein levels of GFM1 (A), TuFM (B), and MRPS7 (C) 24 hr after the indicated DLBCL cell 














Figure 3-S2. ADP-stimulated respiration following tigecycline treatment 
Effects of 20 hr treatment with 1 µM tigecycline on ADP-stimulated (State III) respiration for  
mitochondria isolated from OxPhos- (Pfeiffer, Karpas 422 and Toledo) or BCR- (SU-DHL-6) 
DLBCL cell  lines. Respiration  rates were measured  in the  presence  of  complex  I (CI) or 





























Table  3-S2.  Identification  of  mitochondrial  translation  factors  enriched  in  the 
OxPhos-DLBCL proteome  
Table lists unique peptides identified across each mitochondrial translation factor shown in 
Figure 3.2. The number and list of unique tryptic peptides identified for each protein are 
indicated.  Abundance  ratios  were  derived  by  summing  iTRAQ  reporters  for  all  unique 



















Figure 4-S1. Representative rates of palmitate respiration following mdivi-1 treatment 
Representative oxygen consumption rates (OCR) for one OxPhos-DLBCL (OCI-Ly4) and one 
BCR-DLBCL (SU-DHL-4) cell line supplied with exogenous palmitate following 24 hr mdivi-1 

























Figure 4-S2. Representative traces of oxygen consumption rates on various 
substrates following DRP1-DN expression 
Representative  assay  for  mitochondrial  oxygen  consumption  rates  (OCR)  in  response  to       
2 mM L-glutamine, 0.5 mM hexanoate or 0.2 mM palmitate after 24 hr lentiviral transduction 
with  DRP1-DN.  Data  shown  is  from  one  OxPhos-DLBCL  cell  line  (OCI-Ly4).  Error  bars,        














Figure  4-S3.  Differential  expression  of  TRAP1  in  mitochondria-enriched  heavy 
membrane fractions prepared from DLBCL cell lines 
Western blot analysis of TRAP1 levels in mitochondria-enriched heavy membrane fractions 







Figure 4-S4. DLBCL cell lines contain lipid droplets 
Lipid droplets were visualized using Nile Red in an OxPhos- (Pfeiffer) and BCR- (SU-DHL-4) 
DLBCL cell line. Live cells were incubated for 30 min in 100 nM Mitotracker Green followed 
by labeling with 1 µg/ml Nile Red for 15 min. Images were collected using a Zeiss LSM 710-
Live Duo Scan confocal microscope on live cells immobilized in 0.5% agarose/media. 
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